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Rheumatoid arthritis, pre-rheumatoid arthritis stages and juvenile 
idiopathic arthritis
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that principally affects 
synovial joints. RA is present in 0,5% to 1% of the global population. The incidence of RA 
is higher in women than in men and increases with age (1). RA can affect any joint but 
preferably small joints in hands and feet (2). The symptoms of RA include pain, swelling, 
stiffness, redness, warmth and can finally lead to loss of joint functions (2). The systemic 
symptoms of RA include fatigue, malaise, loss of appetite and muscle ache. Next to 
the joints RA can affect other organs such as skin, lungs, heart and blood vessels (3). RA can 
be classified using the 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria for rheumatoid arthritis (2010 ACR/EULAR criteria) 
(4). This is a quantitative system in which scores can be obtained from: joint involvement, 
serologic markers, inflammation markers and duration of symptoms (4). 
Development of RA can be acute or can be preceded by pre-RA stages. Yet a uniform and 
precise definition of pre-RA stages does not exist. Pre-RA stages generally refer to patients 
who have clinical symptoms involving joints but not fulfill the diagnostic criteria of RA 
or other forms of arthritis (5). Arthralgia and undifferentiated arthritis (UA) are two 
common types of pre-RA stages. Arthralgia patients may have symptoms such as joint pain, 
psychological distress, muscle cramps, abnormal skin sensations, stiffness, loss of motor 
control, weakness, fatigue and sleeping difficulties but have no clinically apparent joint 
swelling/inflammation (6-8). UA patients, to the opposite, have clinically apparent joint 
swelling suggestive of inflammation (9). Patients in these two stages can progress to RA but 
also have high chance of remission (8,9). The likelihood of progression to RA for arthralgia 
and UA patients is partially predictable by clinical and serologic variables. The arthralgia and 
UA patients share the predictable variables: morning stiffness and the presence of anti-cyclic 
citrullinated peptide antibodies (10,11). The arthralgia patients specific prediction variables 
are: rheumatoid arthritis in a first degree family member, alcohol non-use, duration of 
symptoms <12 months, presence of intermittent symptoms, arthralgia in upper and lower 
extremities, visual analogue scale pain≥50, and history of swollen joints as reported by 
the patient (10). The UA patients specific prediction variables are: sex, age, localization 
of symptoms, the tender joint count, the swollen joint count, the C-reactive protein level, 
rheumatoid factor positivity, and magnetic resonance imaging (MRI)/ultra sound pattern 
(11-14). Since these associations apply at a group level additional biomarkers are needed that 
will allow a more personalized medicine approach in these pre-RA patients.
12
Arthritis can also occur in children and is referred to as juvenile idiopathic arthritis 
(JIA), the most common rheumatic disease in children (0,01%-0,4%) consisting of eight 
heterogeneous subgroups (15). A common feature of JIA is joint inflammation resulting 
in pain, loss of function, and morning stiffness (16). Unlike adult RA, JIA patients have 
higher chances of remission and a lower prevalence of autoantibodies (17,18). Rheumatoid 
factor (RF) positive polyarticular JIA is the subgroup which resembles most the clinical and 
immune-genetic characteristics of adult RA patients (15).
Autoantibodies in RA, pre-RA stage and JIA patients
RA patients are a heterogeneous group of patients with pronounced differences in disease 
activity and outcome. This heterogenous group can be subdivided by the presence of 
autoantibodies. Autoantibody positive and negative RA patients were found to have different 
genetic background, disease development processes and responses to treatments (2). 
Currently, RF and anti-citrullinated protein antibodies (ACPA) are two major autoantibody 
systems in RA patients. The identification of RF can be dated back to 1940, reported by Waaler 
et al (19). RF is a polyclonal antibody system which mainly recognizes the Fc part of IgG (20). 
RF is present in about 50%-90% of RA patients but can also be present in other rheumatic or 
non-rheumatic diseases (21). IgM-RF is the most frequently detected isotype in RA patients 
but IgG and IgA isotypes also exist (22). The possible functions of RF include helping 
immune complex (IC) formation and clearance as well as facilitating antigen presentation 
(23). RF was the most important diagnostic marker in RA before ACPA were discovered and 
it is still included in the newest 2010 ACR/EULAR RA classification criteria in the same way 
as ACPA (4). However, the clinical relevance of RF was shown to be limited. Given that IgM-
RF can be detected in sera of blood bank donors who developed to RA several years later but 
not in those who did not develop to RA (24-26), a cross-sectional screening study detected 
only one RA patient in each 10 RF-positive subjects (27). The presence of IgM-RF predicts 
future development of RA in UA patients independent of ACPA (28). However, the presence 
of IgM-RF did not have such predictive value in arthralgia patients, no prognostic value for 
joint damage and for the chances of disease modifying anti-rheumatic drug (DMARD) free 
remission in early RA patients in the disease course independent of ACPA (7,29,30).
The presence of ACPA and their prognostic value in RA patients were first reported around 
50 years later than RF (31). ACPA bind to citrullinated epitopes of auto-antigens. The 
sensitivity of ACPA (~67%) was comparable to IgM-RF (~69%) but its specificity (~95%) 
was much higher than IgM-RF (~85%) (32). The presence and the level of ACPA contribute 
2 points in the newly made 2010 ACR/EULAR RA classification criteria (4). The presence 
of ACPA in early RA patients is associated with worse disease development and a lower 
chance of reaching DMARD free remission (29,30). The presence of ACPA is also associated 













In addition, the presence of ACPA is associated with more severe extra-articular 
manifestations in RA patients (35). ACPA positive UA and arthralgia patients have an 
increased chance of further developing to RA (7) while IgM-RF negative arthralgia 
patients almost do not develop to arthritis (36). ACPA are present in 24% of UA patients in 
the Leiden early arthritis cohort (EAC) and the positive predictive value for developing 
to RA is 67% (28). In addition, around 30% of RA patients developed ACPA before 
the appearance of any clinical symptom (24,25) The presence of ACPA before the onset of 
RA in asymptomatic blood donors is associated with the development of erosive RA (26).
Next to the presence of ACPA, several aspects of the ACPA responses, such as titer, isotype 
usage, epitope spreading and avidity (37-39), are associated with the clinical outcome of RA. 
An increased ACPA isotype usage was observed in RA patients compared to UA and healthy 
individuals who are also ACPA positive (37,40). High titer ACPA positive UA patients 
have a higher risk of developing to RA and a more acute development compared to low 
titer ACPA positive UA patients (38). The number of recognized citrullinated epitopes is 
positively associated with the risk of developing to RA and negatively associated with the 
chance of reaching DMARD free remission in ACPA positive arthralgia and UA patients 
(28,41,42). ACPA positive RA patients who have the lowest quartile avidity (binding 
strength to antigens) also have the most joint damage in their disease course (39). Above 
mentioned associations suggest that the autoantibody response is a developing process and 
it may trigger other symptoms/pathogenic effects of RA.
The autoantibody profile in JIA patients is quite different from adult RA patients. Antinuclear 
antibodies (ANA) have a lower prevalence and diagnostic value in RA patients compared to 
RF (43). But in JIA patients the presence of ANA is associated with a higher risk of uveitis 
and increased T and B cells infiltration (44,45). The prevalence of RF or ACPA in JIA patients 
is less than in adult RA patients and is predominantly confined in RF-positive polyarticular 
JIA subgroup (17,46). Like in adult RA, ACPA were confirmed as an independent risk factor 
associated with worse disease outcome in JIA patients (47,48).
In summary, both ACPA and RF are diagnostic markers for RA patients and predictive 
markers for future development of RA in pre-RA stage patients. ACPA are also a prognostic 
marker in RA patients.
Genetic predisposing and ACPA
As described before, RA patients can be divided into 2 distinct subsets which, at a group 
level, have different disease courses and genetic risk profiles based on ACPA positivity 
(49). This again suggests that the production of ACPA is a key intermediate step between 
the predisposing genetic risk and the development of RA. Eventhough the heritability of 
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ACPA negative and positive RA patients are both estimated to be about 66% (50), yet no 
predominant human leukocyte antigen (HLA) association and far less non-HLA risk single-
nucleotide polymorphisms (SNPs) were found in association with ACPA negative patients 
(51-53).  The most important genetic risk factors of ACPA positive RA reside in the Human 
Leukocyte Antigen (HLA) class II locus, more specifically the shared epitopes (SE) on HLA-
DR beta 1 (HLA-DRβ1). SE consists of three homologous amino acid sequence variants 
in residues 70–74 of the HLA-DRβ chain: QKRAA, QRRAA and RRRAA (54). HLA SE 
alleles contribute 18% of the susceptibility of ACPA-positive RA patients (50).  In non-HLA 
genes which have SNPs associated with higher risk of developing to ACPA-positive RA (52), 
many genes encode proteins which are potentially contributive to autoantibody production 
or immune complex activated pathways. Thus both HLA and non-HLA genetic risk factors 
of RA suggest the pathogenesis of ACPA positive RA patients is perhaps predominantly 
initiated via adaptive immunity.
Environmental risk factors and ACPA
Beside genetic risk factors, also environmental risk factors such as cigarette smoking and 
infection are associated with a higher risk of developing to RA. Cigarette smoking is dose 
dependently associated with the susceptibility of RA and disease progression (55-57). It is 
also strongly associated with the combined presence of ACPA positivity and SE (55,56,58). 
Increased expression of peptidyl-arginine deiminase (PAD) induced by smoking is one 
hypothesis to explain the effect of smoking in RA patients and its association with ACPA 
positivity and SE (59). Periodontitis (PD), an infectious disease, is also associated with 
a higher incidence and severity of RA (60-62). Treatment of PD in established RA patients 
decreased the severity of RA (63-65). The presence of PD and the level of antibodies 
against P. gingivalis, a pathogen of PD, are associated with the presence of ACPA and 
RF-IgM (66,67). NETosis of neutrophils is another mechanism which can be triggered 
by the pathogens of PD (68). NETosis, a process in which the nuclear content of cells is 
extruded from the cell, will release intracellular PAD4, which offers another source for 
extracellular citrullination (69). 
Pathological functions of ACPA
To explain the potential contribution of ACPA to the pathogenesis of RA, the functions 
of ACPA have been studied in several aspects. ACPA, citrullinated antigens and their 
immune complex (IC) were reported to induce the TNF-α production of several cell types 
including macrophage, monocyte, fibroblast-like synoviocytes and osteoclast precursors 
(70-72). TNF-α is a key cytokine in the pathogenesis of RA (73). Furthermore, ACPA 
stimulate osteoclastogenesis and osteoclast mediated bone erosion. In addition ACPA have 
been shown to activate the classical and alternative pathways of complement (74). ACPA 













antigens depending on their genetic background (75). However, whether ACPA play a role 
in the progression of the disease in DBA1 and Balb/c mice is in debate (76-78).
Carbamylation
As ACPA are only present in about 67% of the RA patients and as part of the ACPA 
negative RA patients also have severe joint damage, there is a need for additional 
biomarkers to identify ACPA negative patients in need of a more aggressive intervention 
(79).  In an attempt to identify additional biomarkers to be used for such identification 
we addressed the presence of antibodies directed against proteins modified by another 
form of post-translational modification, carbamylation. Homocitrulline is an amino acid 
with a high structural similarity to citrulline and therefore we hypothesized that anti-
homocitrulline containing (carbamylated) protein antibodies may also be present in some 
RA patients and we tested this hypothesis following previous studies on carbamylation 
as described in detail below.
Pathways that induce carbamylation of proteins
Carbamylation: cyanate reacting to primary amino or thiol groups
Carbamylation is a post-translational modification in which cyanate reacts to primary 
amino or thiol groups. The reaction of cyanate to either amino groups or thiol groups 
is specified as N-carbamylation or S-carbamylation. Beside the N-terminus of all 
proteins, the amino acids lysine, arginine and cysteine contain side chains that can 
react with cyanate (80,81). However, since carbamylation on side chains of cysteine and 
arginine, the N-terminus of proteins and free amino acids is rarely reported we therefore 
here refer to carbamylation as cyanate reacting on peptidyl-lysine without further 
specification. Urea is a source of cyanate in all individuals and is present in body fluids 
in equilibrium with ammonium cyanate (Fig. 1). The equilibrium ratio between cyanate 
and urea has been suggested to be around 1 to 500.000 (82). Despite the low concentration 
of cyanate, trace amount of carbamylation can be detected in healthy individuals (83,84). 
As expected, elevated carbamylation was extensively reported among patients with renal 
dysfunction and elevated blood urea nitrogen (BUN) levels (85-87).
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Figure 1. Pathways involved in in vivo cyanate generation
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Inflammation increases the level of cyanate
In addition to renal insufficiency, inflammation is another factor which can stimulate 
the degree of carbamylation. Wang and Holzer et al. demonstrated that inflammation can 
enhance carbamylation via a mechanism which depends on myeloperoxidase (MPO) (88,89). 
MPO is mainly stored in granules of neutrophils (90) and it can generate cyanate using 
hydrogen peroxide and thiocyanate as substrates. Thiocyanate, derived from e.g. food or 
smoke exposure (88), can be oxidized by hydrogen peroxide with the help of MPO, resulting 
in the formation of hypothiocyanate (84) which decomposes to cyanate and other ions (91). 
In addition MPO can also catalyze the reactions between hydrogen peroxide and chloride 
(90) that via a series of reactions leads to increased levels of cyanate (Fig. 1) (89). The marked 
increased levels of MPO in inflammation (92) therefore stimulates the formation of cyanate. 
These findings indicate that MPO released from neutrophils can further increase the level of 
carbamylation during inflammation.
Direct inhalation of cyanate
Cyanate (~200 parts-per-trillion volume) can also be directly inhaled from urban air. A five 













already generate an aqueous solution of 100 μM (93). This concentration is equal to or higher 
than the effective dose of cyanate which is able to cause notable effects in several in vitro 
studies (94-96). Cyanate in air can be derived from various sources such as biomass burning, 
coal burning, biofuel usage, cooking, tobacco usage and wild fire. Even in the absence 
of inflammation the direct exposure to air borne cyanate can be sufficient to generate 
low levels of carbamylation. 
Lysine carbamyltransferase converts free amino acid lysine to 
homocitrulline
Beside above mentioned mechanisms, carbamylation on free amino acids can also be 
catalyzed by the enzyme lysine carbamyltransferase. This enzyme converts the free amino 
acid lysine and carbamyl phosphate to homocitrulline (97,98). Whether this enzyme is 
able to catalyze the reaction between carbamyl phosphate and peptidyl-lysine has, to 
the best of my knowledge, not been studied. Carbamyl phosphate injected in rats caused 
extensive carbamylation (99). Thus leaking of carbamyl phosphate synthetase or lysine 
carbamyltransferase due to apoptosis or necrosis of cells might potentially be a currently 
unexplored source of introducing carbamylation. At this stage, protein carbamylation 
mediated by enzymes seems unlikely but clearly requires further investigation.
Effects of carbamylation in (patho)physiology
Consequences of carbamylation have been reported to occur at the protein, cellular and 
systemic level. Decreased activity upon carbamylation has been reported for several enzymes 
and hormones, (100-105). Altered binding affinity to target ligands upon carbamylation 
has also been reported on hemoglobin A and human serum albumin (106-109). Other 
reported effects of carbamylation on proteins include changing their polymerization ability 
(collagen and actin), sensitivity to proteinases (collagen and glutamate dehydrogenase) and 
antibody antigen binding avidity (blood group specific glycoprotein) (110-112). 
Not surprisingly, carbamylation of proteins and small molecules has an impact on normal 
cellular functions. Exposure to relatively high concentrations of cyanate is cytotoxic, which 
has been reported for e.g. human erythrocytes (114,115). Lower levels of carbamylation 
may also change cellular functions in several ways as described below. For example, in 
vitro incubation with cyanate dose-dependently decreased protein synthesis of rat bone 
marrow cells (108), insulin secretion of pancreatic β cells (95), the respiration rate of 
rat mitochondria (116) and ROS production of human neutrophils (117). Next to a role 
of cyanate on cellular functions also the interaction with carbamylated proteins has an 
impact on cellular functions. For example, carbamylated BSA increased collagen production 
of mesangial cells (118-120) and adhesion of monocytes onto carbamylated collagen was 
significantly enhanced (121). 
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As a consequence of the effects on protein and cellular functions, carbamylation may also 
trigger systemic effects. Cyanate is one of the agents which have been used to treat sickle 
cell anemia patients (122,123). However, neurotoxicity and cataract were observed as 
side effects. More than half of sickle cell anemia patients who received cyanate treatment 
developed nerve conduction abnormalities (124). Similar to neurotoxicity, cataract was also 
reported as a side effect in sickle cell disease patients treated with cyanate (125). 
As mentioned above, patients suffering from uremia have increased levels of carbamylation 
due to high level of urea (126-128). The quantity of carbamylation is also associated with other 
renal function markers such as creatinine, cystatin C and estimated glomerular filtration rate 
(129-131). Since the degree of carbamylation is associated with these other markers of renal 
function, it is not easy to judge the independent contribution of carbamylation to kidney 
dysfunction. Two recent findings regarding the prognostic value of carbamylated proteins 
in end stage renal disease (ESRD) may suggest that carbamylation is an independent risk 
factor in the progression of renal dysfunction (131). ESRD is the last stage of chronic 
kidney disease (CKD) in which kidney failure is permanent and medical interventions 
(dialysis or kidney transplantation) are compulsory for patients to survive. Baseline 
percentage of carbamylated Lys549 on albumin appeared to be the risk factor with 
the highest hazard ratio for mortality in two independent ESRD cohorts after correcting for 
all other known risk factors (132). This was recently independently confirmed (131).
Similar to CKD, increased levels of carbamylation are also observed in cardiovascular disease 
(CVD) which is associated with adverse clinical events. Increased carbamylation levels of 
plasma protein were found in patients with atherosclerotic CVD and systolic heart failure 
compared to healthy controls and was associated with developing adverse clinical events of 
these patients even after correcting other risk factors (88,130). The degree of carbamylation 
on high density lipoprotein (HDL) in the lesions of atherosclerosis patients is also correlated 
with the severity of the lesions and MPO mediated oxidative stress (133).
Induction of antibody responses against carbamylated proteins
Post-translationally modified proteins have been described to have the capacity to break 
immunological tolerance and induce autoantibody responses (134-136). The notion that 
this can also occur in the setting of carbamylation was initiated by Steinbrecher et al. who 
reported immunization experiments with carbamylated proteins (137). This hypothesis 
was also supported by the presence of anti-CarP antibodies as described for animal models 
previously. Both rabbits (138) and mice (139,140) were shown to be able to develop antibody 
responses against homocitrulline containing antigens upon immunization with peptides 
containing homocitrulline or carbamylated proteins. Besides, the presence of antibody 













these previous studies, we aimed to investigate the presence of anti-CarP antibodies in RA, 
pre-RA stages and JIA patients and whether they have similar diagnostic, predictive and 
prognostic value in these patients as ACPA and RF.
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Abstract
Autoimmune responses against posttranslationally modified antigens are a hallmark 
of several autoimmune diseases. For example, antibodies against citrullinated protein 
antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid 
arthritis (RA), and have been implicated in disease pathogenesis. It is conceivable that other 
autoantibody systems, recognizing other posttranslationally modified proteins, are also 
present in RA. Here, we describe the presence of an autoantibody system that discriminates 
between citrulline- and homocitrulline-containing antigens in the sera of RA-patients. IgG 
antibodies recognizing carbamylated (homocitrulline-containing) antigens were present 
in sera of over 45% of RA-patients. Likewise, anticarbamylated protein (anti-CarP) IgA 
antibodies were observed in 43% of RA-sera. ACPA and anti-CarP antibodies are distinct 
autoantibodies because, in selected double-positive patients, the anti-CarP antibody binding 
to carbamylated antigens could be inhibited by carbamylated antigens, but not by control 
or citrullinated antigens. Similarly, ACPA-binding to citrullinated antigens could only be 
inhibited by citrullinated antigens. In line with this observation, 16% of ACPA-negative 
RA-patients, as measured by a standard ACPA assay, harbored IgG anti-CarP antibodies, 
whereas 30% of these patients tested positive for IgA anti-CarP antibodies. The presence of 
anti-CarP antibodies was predictive for a more severe disease course in ACPA-negative 
patients as measured by radiological progression. Taken together, these data show 
the presence of a unique autoantibody system recognizing carbamylated, but not 
citrullinated, protein antigens. These antibodies are predictive for a more severe clinical 
course in ACPA-negative RA-patients, indicating that anti-CarP antibodies are a unique and 














The identification of anticitrullinated protein antibodies (ACPA) has contributed significantly 
to the understanding of rheumatoid arthritis (RA) (1). Significant differences between 
 ACPA-positive and -negative disease have been reported with respect to the contribution of 
genetic and environmental risk factors, as well as disease progression and remission (2–5). Over 
the past few years important insight has been gained into the occurrence and etiophathology 
of ACPA-positive RA. However, less information is available on ACPA-negative RA. 
This lack of information is partly because of the absence of robust biomarkers characterizing 
this manifestation of RA.
The posttranslational modification of arginine into citrulline by peptidyl arginine deiminase 
(PAD) enzymes is essential for the generation of citrullinated antigens that are recognized 
by ACPA (1). Under physiological circumstances, citrullination is involved in tissues like 
hair and skin because of its role in terminal epithelial differentiation (6). In the nucleus 
citrullination plays a role in epigenetic regulation (7) and condensation of chromatin, and 
has been reported to be involved in translation (6) and the host defense against pathogens 
(8). Under pathological conditions where cell death may overwhelm the phagocytic 
capacity of phagocytes, necrotic cells may release PAD into the extracellular space, 
where higher calcium concentrations now also allow the citrullination of other proteins 
located outside the cell (6). These proteins may be targeted by ACPA, possibly leading to 
inflammation and arthritis.
Citrulline highly resembles homocitrulline (Fig. 1), another posttranslationally modified 
amino acid (9). Homocitrulline is one methylene group longer, but similar in structure 
(9). Homocitrulline is generated from a lysine residue following a reaction of cyanate, 
which is present in the body in equilibrium with urea. Under physiological conditions 
the urea concentration may be too low to allow extensive carbamylation but the conversion 
process leading to the formation of homocitrulline from lysine in proteins does occur in 
vivo. In conditions of renal failure, the urea concentration increases and carbamylation of 
many proteins can be readily detected. However, most carbamylation is believed to take 
place during inflammation when myeloperoxidase is released from neutrophils (10). 
This enzyme converts thiocyanate to cyanate, now allowing more carbamylation to occur 
(11). It has been shown recently that homocitrulline-containing proteins are present in 
the RA joint and that they may affect T-cell triggering and possibly autoantibody formation in 
rodents (9, 12). Although highly similar, carbamylation differs from citrullination as, next to 
their structural difference, lysine is modified instead of arginine. Therefore, homocitrulline 
will, by definition, be located at other positions in proteins than citrulline. Because of the 
similarity between citrulline and homocitrulline, In this chapter we analyzed whether 
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autoantibodies against carbamylated proteins are present in RA and whether these antibodies 
differ from ACPA with respect to antigen binding and clinical associations.
Figure 1. Illustration of citrullination and carbamylation. Citrullination (A) and carbamylation 









































































Anticarbamylated protein antibodies and ACPA are different  
antibody families
To detect antibodies against carbamylated proteins (anti-CarP antibodies), we developed 
an ELISA using carbamylated FCS (Ca-FCS) and nonmodified FCS as antigens. 
Analyzing sera of 40 RA patients and 40 controls, we observed that sera of RA-patients 
reacted with Ca-FCS compared with sera obtained from healthy subjects with both 
IgG (Fig. 2 A and B) and IgA (Fig. 2 D and E) reactivity. The enhanced reactivity of 
RA sera to Ca-FCS is further emphasized after subtraction of the reactivity against 
unmodified FCS (Fig. 2 C and F). Because citrulline and homocitrulline are two rather 













homocitrulline when located at the same position as citrulline in a peptide. For this purpose 
we performed ELISAs using a citrullinated Fibrinogen (Fib) peptide known to be recognized 
by ACPA (13). Within this peptide backbone, a citrulline, an arginine, a homocitrulline, 
or a lysine residue was introduced for further analysis. Analyzing a set of 76 RA sera, we 
observed that ACPA only recognized the citrullinated peptide, but not the arginine-
containing or the homocitrulline-containing peptide (Fig. 3A). These data indicate that 
ACPA can discriminate between citrulline and homocitrulline presence within the same 
peptide backbone. Next, we wished to analyze whether there is cross-reactivity between 
anti-CarP antibodies and ACPA for binding to posttranslationally modified proteins. 
Therefore, we performed inhibition studies using sera that were reactive to both citrullinated 
and carbamylated antigens. We analyzed the binding of anti-CarP antibodies to Ca-FCS–coated 
plates following preincubation with Ca-FCS, citrullinated FCS (Ci-FCS), native FCS, or by 
citrullinated peptides used to detect ACPA (cyclic citrullinated peptide-1, CCP1). Following 
preincubation, we observed that anti-CarP antibody binding to Ca-FCS can only be inhibited 
by Ca-FCS but not by Ci-FCS, native FCS, or by peptides used to detect ACPA (Fig. 3B). 
We also performed the reverse inhibition experiment where we analyzed the binding of ACPA 
to plates coated with Ci-FCS following the same preincubation procedure. We observed 
that ACPA binding to Ci-FCS could only be inhibited by Ci-FCS and the citrullinated 
peptide but not by Ca-FCS, nonmodified FCS, or the arginine form of the peptide 
(Fig. 3C). Taken together, these data indicate that anti-CarP antibodies and ACPA are not, 
or only limited, cross-reactive and specifically directed against homocitrulline or citrulline-
containing antigens, respectively. Because all observations described above were made using 
ELISA, we also wished to confirm our findings using a different technique. For this reason 
we performed a Western blot-analysis using FCS, Ca-FCS, and Ci-FCS on reduced gels, 
followed by Western blotting. The different blots were incubated with sera of individuals 
that were either anti-CarP–positive and ACPA-negative or anti-CarP–negative and ACPA-
positive. We observed a positive staining of the anti-CarP–positive sample only on Ca-FCS 
but not on Ci-FCS or FCS (Fig. 3D). In contrast, the anti-CarP–negative, ACPA-positive 
sample reacted to Ci-FCS, but not to Ca-FCS and FCS (Fig. 3D). To confirm the presence 
of anti-CarP antibodies we repeated these experiments using a more defined protein, 
human Fib, as a target antigen. Fib was citrullinated by PAD (Ci-Fib) or carbamylated by 
cyanate (Ca-Fib). The nonmodified form (Fib), Ci-Fib, and Ca-Fib were used as antigens in 
ELISA. Similar to the observations for FCS, we observed significant binding of antibodies to 
the Ci-Fib and the Ca-Fib but not to the Fib-coated wells (Fig. 4A). This finding was largely 
restricted to the RA sera and not the controls (P ≤ 0.0001). To analyze cross-reactivity 
we also performed inhibition studies, as described above. ELISA analyses confirmed 
that ACPA and anti-CarP antibodies are largely noncross-reactive (Fig 4B). To ensure 
that reactivity toward carbamylated proteins is mediated by the antigen-binding part of 
the antibodies, we generated F(abʹ)2. As expected, F(abʹ)2, generated from anti-CarP IgG-
positive samples but not from negative samples display anti-CarP reactivity (Fig. 4 C and D). 
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As observed using intact antibodies, F(abʹ)2-reactivity toward Ca-Fib could also be inhibited 
specifically by Ca-Fib, whereas F(abʹ)2-reactivity toward Ci-Fib could only be inhibited 
specifically by Ci-Fib (Fig. 4E).
Figure 2. Antibodies against carbamylated proteins are present in sera of RA patients. 
The reactivity of IgG (A and B) and IgA (D and E) from sera of healthy controls (NHS) or RA 
patients (RA) to wells coated with nonmodified FCS (FCS) or carbamylated FCS (Ca-FCS) is 
depicted. Data expressed as absorbance at 415 nm. (C and F) Absorbance units of FCS were 
subtracted from the absorbance units of Ca-FCS, representing the specific anticarbamylated 













Figure 3. Anti-CarP antibodies and ACPA are two separate autoantibody systems. 
IgG reactivity of 76 sera from RA patients, toward several forms of a Fib peptide is depicted. 
(B and C) Antibody binding to Ca-FCS or Ci-FCS was inhibited using preincubations with fluid-
phase inhibitors. (D) FCS, Ca-FCS, and Ci-FCS were separated by SDS-PAGE gels and blotted. 
The presence of antibodies reactive to proteins on the blots was analyzed by incubating these 
blots with either anti-CarP–positive ACPA-negative and anti-CarP–negative ACPA-positive sera.
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Figure 4. Anti-CarP antibodies bind to Ca-Fib via variable domains. (A) IgG reactivity 
against Fib, Ci-Fib, and Ca-Fib of 54 healthy controls and 214 RA patients was analyzed 
by ELISA. (B) Specificity of anti–Ca-Fib reactivity was confirmed using inhibition studies. 
One sample is shown, where data are expressed relative to inhibition with PBS. (C) 
The molecular nature of purified IgG and F(abʹ)2 was confimed by Coomassie-stained SDS-
PAGE gel. (D) F(abʹ)2 fragments were generated from purified IgG of 2 anti-CarP–positive 
patients and two negative controls. Only F(abʹ)2 from patients reacted with Ci-Fib and Ca-
Fib. (E) Inhibition experiments confirm that also F(abʹ)2 are not necessarily cross-reactive 
between Ci-Fib and Ca-Fib.
Collectively, these data indicate that anti-CarP antibodies and ACPA recognize different 
antigens, one recognizing citrullinated proteins (ACPA) and the other carbamylated proteins 
(anti-CarP). Likewise, these data indicate that antigen-recognition is most likely mediated 
via the variable domains present in the F(abʹ)2 fragments.
Anti-CarP antibodies are present in RA
Following the identification of anti-CarP antibodies as an autoantibody family separate 
from ACPA, we wished to quantify the presence of these anti-CarP antibodies in a large 
population of RA patients and controls. For this reason, we first generated a standard, 
comprising of a pool of anti-CarP antibody-positive sera. This standard displayed a specific, 
dose-dependent binding of both IgG and IgA to Ca-FCS but no binding to unmodified 
FCS (Fig. 5 A and B). For this analysis, we again used the FCS-based assay in an attempt 
to capture as many anti-CarP reactivities as possible. We established a cutoff for positivity 
using sera of 305 healthy individuals, as described in Materials and Methods. Using this 













anti-CarP antibodies (Fig. 5C). Likewise, 43% of sera from RA patients tested are positive for 
IgA anti-CarP antibodies (Fig. 5D).
Figure 5. Anti-CarP IgG and IgA antibodies are present in RA sera. (A and B) Dose-
response curves of the anti-CarP antibody-positive standard (IgG and IgA) on Ca-FCS and 
FCS in ELISA. (C and D) ELISA was performed for the detection of anti-CarP IgG and IgA 
in sera of healthy controls (NHS) and RA patients. A cut-off was established using the mean 
plus two times the SD of the healthy controls, as described in the Materials and Methods. 
Reactivity is depicted as arbitrary units per milliliter. The number of samples tested and 
the percentage of positivity is indicated below the graph. (E and F) Pie charts showing 
the percentage of RA patients positive and negative for anti-CCP2 and anti-CarP antibodies. 
(G and H) Pie charts showing the percentage of anti-CarP IgG- or IgA-positive patients 
negative for anti-CCP2.
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Anti-CarP antibodies are also present in sera of anti-CCP2–negative 
RA patients
The group of RA patients analyzed in this study consisted of both ACPA-positive and 
ACPA-negative individuals, as measured by the CCP2 assay. Therefore, we analyzed next 
the association between anti-CarP antibodies and anti-CCP2 antibodies. The presence of 
anti-CarP antibodies and anti-CCP2 antibodies showed a limited degree of correlation when 
analyzing the entire RA population (r2 = 0,27, p < 0,001 for anti-CarP IgG or r2 = 0,15, p 
< 0,001 for IgA). However, we also identified substantial numbers of RA patients that are 
only positive for anti-CCP2 antibodies, as well as a group of patients that is only positive for 
anti-CarP antibodies (Fig. 5 E and F). We observed that ~16% of the anti-CCP2–negative 
RA patients displayed anti-CarP IgG antibodies, whereas 30% of the anti-CCP2–negative 
RA patients tested positive for anti-CarP IgA (Fig. 5 G and H). These data indicate that 
the presence of anti-CarP antibodies overlaps with the occurrence of anti-CCP2 antibodies, 
but that this overlap is not absolute, as over 30% of the anti-CCP2–negative patients harbor 
anti-CarP antibodies. In total, more than 35% of all anti-CCP2–negative patients have either 
anti-CarP IgG or IgA antibodies.
Anti-CarP antibodies are associated with more severe  
radiological damage
The presence of ACPA is associated with a more severe clinical disease course as measured 
by radiological damage. To analyze whether the presence of anti-CarP antibodies 
are also predictive for a more severe disease course, we compared the extent of joint 
damage over time between anti-CarP–positive and –negative patients participating 
in the Leiden Early Arthritis Clinic (EAC) cohort. This cohort is an inception cohort of 
patients with recent-onset arthritis where X-rays of hands and feet are taken of all RA-
patients at yearly intervals to assess radiological damage using the Sharp–van der Heijde 
method (14). We observed that the presence of anti-CarP IgG strongly associates with 
a more severe disease progression. Patients positive for anti-CarP IgG had more joint 
destruction over 7 y than IgG-negative patients without [β = 2,01, 95% confidence interval 
(CI) 1,68–2,40, p = 8,68 × 10−14] or with correction of ACPA and rheumatoid factor (RF) 
(β = 1,41, 95% CI 1,13–1,76, p = 0,002) (Fig. 6A). Anti-CarP IgA was associated with more joint 
destruction over 7 y than anti-CarP IgA-negative patients without correction of ACPA and RF 
(β = 1,21, 95% CI 1,01–1,45, p = 0,041) but not after correction (p = 0,855) (Fig. 6D). As the analysis 
described above does not show whether anti-CarP antibodies predict radiological progression in 
the anti-CCP2–negative, anti-CCP2–positive, or both RA subgroups, we next performed 
a stratified analysis. Importantly, this analysis revealed that the presence of anti-CarP 
IgG is associated with a more severe joint damage in the anti-CCP2–negative subgroup 
(β = 1,86, 95% CI 1,41–2,66, p = 1,8 x 10−5) (Fig. 6B). Likewise, a similar trend toward more 













for IgA anti-CarP antibodies (β = 1,25, 95% CI 0,98–1,58, p = 0,071) (Fig. 6E). In contrast, in 
the anti-CCP2–positive subgroup, which is already characterized by severe joint destruction, 
no additional increase was observed in individuals who also harbored anti-CarP antibodies 
(Fig. 6C&F). Taken together, these data indicate that the detection of anti-CarP antibodies 
at baseline is predictive for a more destructive disease course in anti-CCP2–negative RA as 
measured by the Sharp–van der Heijde method.
Figure 6. Anti-CarP IgG antibodies are associated with a more severe radiological progression 
in RA. The extent and rate of joint destruction were analyzed in all RA patients included, or 
analyzed separately for ACPA-negative or ACPA-positive subgroups. The severity of joint 
destruction of anti-CarP IgG-positive versus -negative patients is depicted as median Sharp-van 
der Heijde score (SHS) on the y axis and the follow-up years on the x axis. Below the x axis, 
the patient number is listed for each time point. (A) Radiological progression for all RA patients 
analyzed, or for the (B) anti-CCP2–negative, or (C) anti-CCP2–positive patients only. Similarly, 
the effect of anti-CarP IgA antibodies on severity is depicted for (D) the RA group as a whole, or 
(E) for anti-CCP2–negative patients only, or (F) anti-CCP2–positive patients only. The P values 
indicated in the figure are derived from the analysis model following corrections, as described in 
Materials and Methods and Results.
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Discussion
A family of autoantibodies that recognize carbamylated proteins, anti-CarP antibodies, can 
be detected in sera of RA patients. Both inhibition studies and cohort studies show that 
anti-CarP antibodies and ACPA represent two different and independent autoantibody 
families, one recognizing carbamylated proteins and the other citrullinated proteins. 
Our data show that anti-CarP antibodies and ACPA are, by and large, noncross-reactive 
although we do not exclude that some cross-reactivity exists at the population level, as is also 
indicated in recent data obtained in rabbits after vaccination with carbamylated proteins 
(12). Interestingly, positivity for anti-CarP antibodies is related to clinical outcome, as 
individuals positive for anti-CarP IgG, but negative for anti-CCP2 antibodies, have a more 
destructive disease course compared with anti-CarP IgG-negative RA patients.
It is currently unknown which proteins undergo posttranslational modifications like 
carbamylation. Carbamylation is mediated by cyanate, which is in equilibrium with urea. 
Increased urea concentrations, smoking, and inflammation have been reported to shift this 
equilibrium towards cyanate and, hence, enhanced carbamylation (11). Because currently 
no in vivo relevant targets for anti-CarP antibodies are known, we used a complex protein 
mixture as an initial source of carbamylated protein antigens for the detection of anti-CarP 
antibodies. Western blot analyses indicate the recognition by anti-CarP antibodies of at 
least one dominant protein present in FCS after carbamylation using cyanate (representing 
high urea concentrations) (Fig. 3D). However, these data are likely not to represent the in 
vivo situation where carbamylation is a more gradual but constantly occurring process (15). 
In this respect, it is likely that especially long-lived proteins acquire homocitrulline residues 
over time, as carbamylation is nearly irreversible and thus will lead to the accumulation of 
homocitrulline-residues on proteins with a long half-life. Intriguingly, the joint is known for 
the presence of long-lived proteins, such as collagens and other cartilage-expressed proteins. 
Therefore, it is conceivable that such matrix-proteins will accumulate homocitrulline 
residues during life, especially under conditions of inflammation. Indeed, it has been shown 
that homocitrulline is present in the joint (9), possibly representing the long-lived nature of 
many joint-derived proteins. It will be interesting to know the identity of these proteins and 
whether these can serve as a target for anti-CarP antibodies.
The molecular nature of the antigens recognized by ACPA has been identified more than 
15-y ago by describing that citrulline is an essential constituent of antigens recognized by 
these RA-specific antibodies (16, 17). This finding has made considerable impact, as it has 
opened up the way to relevant and novel insights into RA-diagnosis and etiopathology 
(1). For example, ACPA are now part of the new American College of Rheumatology/
European League Against Rheumatism criteria for RA (18), and have been implicated in 













Importantly, the description of ACPA has led to the realization that RA constitutes at least 
two clinical syndromes that share many clinical features, but differ with respect to genetic 
background, predisposing environmental factors and clinical progression/remission 
(3, 4, 26–28). Although it is clearly too early to allow any firm conclusions, it is tempting 
to speculate that anti-CarP antibodies also contribute to disease pathogenesis and display 
diagnostic value, given the similar nature of the antigens recognized and their presence in 
ACPA-negative disease.
The presence of anti-CarP antibodies in anti-CCP2–negative disease is highly intriguing, 
as it could potentially represent a unique biomarker that positively identifies at least part 
of this manifestation of RA. To gain further insight into this possibility, it is important to 
establish whether the presence of anti-CarP antibodies is specific for RA or also found in 
other rheumatic diseases, as well as whether their presence predict the development of 
(ACPA-negative) RA in patients suffering from early unclassified RA and joint complaints, 
such as arthralgia.
To establish a cut-off to define a positive sample, we have analyzed the presence of IgG and 
IgA directed against Ca-FCS and FCS in sera of healthy controls. All samples were tested 
for reactivity toward Ca-FCS and FCS, and absorbance values were converted into arbitrary 
units per milliliter using an anti-CarP antibody-positive standard present on the same plate. 
Because sera from several individual subjects also displayed reactivity toward nonmodified 
FCS, we subtracted the “FCS-reactivity” from the reactivity toward Ca-FCS using arbitrary 
units per milliliter as defined by the standard curve. We subsequently calculated the cut-
off as the mean plus two times SD and applied the cut-off to the data of the RA patients 
following a similar strategy. The disadvantage of this method is that a standard is used 
on Ca-FCS for the determination of arbitrary units per milliliter toward FCS, another 
antigenic entity. However, this method did allow the calculation of a specific response to 
the posttranslational modification.
Every method of establishing a cut-off has advantages and limitations. Therefore, we 
subsequently confirmed our observations using another strategy as well by calculating 
the cut-off as the mean plus two times SD of the anti-Ca- FCS response in controls. This cut-
off was applied to the data of the RA patients as was also used before (29). The association 
with radiological progression of anti-CarP IgG in ACPA-negative RA remains significant, 
albeit with a lower level of significance (p = 0,001).
From a clinical perspective, the detection of anti-CarP antibodies in early arthritis could 
be highly rewarding because they predict a more severe disease course. Because early 
aggressive treatment in RA has been shown to prevent future damage (30, 31), the detection 
of anti-CarP antibodies might be beneficial to identify anti-CCP2–negative patients at risk 
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to develop severe disease. The identification of such patients might be important to guide 
treatment decisions early after onset of symptoms, especially in early arthritis patients that 
are difficult to classify.
In conclusion, in addition to the autoantibody system that recognizes citrullinated proteins 
(ACPA), an autoantibody system against carbamylated proteins (anti-CarP) is present in sera 
of RA patients. Detection of anti-CarP antibodies could offer new possibilities to identify 
patients at risk for a severe disease course.
Materials and methods
Generation of antigens
As we did not know whether antibodies against carbamylated proteins (anti-CarP) would 
be present in sera of rheumatoid arthritis (RA) patients, or which proteins they would 
recognize, we set out to study a diverse set of carbamylated proteins, to maximize the chances 
to detect as many of the anti-CarP reactivities. For this purpose we have used FCS (Bodinco) 
that was carbamylated, citrullinated, or left untreated. For generating carbamylated FCS 
(Ca-FCS), FCS was diluted in H2O to 4 mg/mL and potassium cyanate (Sigma) was added 
to a concentration of 1 M. Following incubation at 37 °C for 12 h, the sample was extensively 
dialyzed against H2O. Carbamylated fibrinogen (Ca-Fib) was generated by incubating 
5 mg/mL fibrinogen (Fib) with 0.5 M potassium cyanate at 4 °C for 3 d followed by being 
extensively dialyzed against PBS. Citrullinated FCS (Ci-FCS) and citrullinated fibrinogen 
(Ci-Fib) was generated by incubation of 10 mg FCS or Fib in a volume of 1 mL containing 
0.1M Tris-HCl pH 7.6, 0.15 M CaCl2, and 40 U PAD4 (Sigma) for 24 h at 37 °C. We have 
confirmed the presence of citrulline and homocitrulline residues using mass-spectrometry 
analysis. For Fib we observed, in the protein segments that we analyzed, extensive 
citrullination and complete carbamylation. 
Detection of anti-CarP antibodies by ELISA
Nonmodified FCS and modified-FCS were coated at 10 μg/mL in 50 μL 
[diluted in pH 9.6 0.1 M carbonate-bicarbonate buffer (CB)] on Nunc Maxisorp plates 
(Thermo Scientific), overnight. Following washing in PBS containing 0.05% tween (Sigma) 
(PT), the plates were blocked by incubating 100 μL PBS/1% BSA (Sigma) for 6 h at 4 °C. 
Following additional washing, the wells were incubated with 50
μL serum at a 1/50 dilution in PBS/0.05% tween/1% BSA buffer (PTB) on ice overnight. 













of positive sera were used. Human IgG or IgA was detected using rabbit anti-human IgG 
antibody (Dako) or rabbit anti-human IgA antibody (Dako) incubated on ice for 3.5 h. 
Following washing, wells were incubated on ice for 3.5 h with HRP-labeled goat anti-rabbit 
IgG antibody (Dako). Following the last washings HRP enzyme activity was visualized 
using ABTS, as described previously (1). Sera of healthy subjects (n = 305) were used as 
controls. We transformed the absorbance on both Ca-FCS and FCS to arbitrary units per 
milliliter (aU/mL) and subtracted the background signal (aU/mL) of FCS from the signal 
(aU/mL) of Ca-FCS as to analyze the specific anti-CarP reactivity (Fig. 2). We established 
the cut-off for a positive response as the mean plus two times the SD of the specific anti-CarP 
reactivity of the healthy controls.
ELISA for fibrinogen
Nonmodified Fib Ci-Fib and Ca-Fib were coated at 20 μg/mL in 50 μL 
(diluted in pH 9.0 PBS) on Nunc
Maxisorp plates overnight. Following washing in PT, the plates were blocked 
by incubating 200 μL pH 9.0 PBS/2% BSA for 2 h at 4 °C. Following additional 
washing, the wells were incubated with 50 μL serum at a 1/50 dilution in RIA buffer 
(10 mM Tris pH 7.6; 350 mM NaCl; 1% TritonX; 0.5% Na-deoxycholate; 0.1% SDS) (Sigma) 
on ice for 3 h. All subsequent incubations are performed in RIA buffer. As a standard, serial 
dilutions of a pool of positive sera were used. Human IgG was detected using HRP-labeled 
rabbit anti human IgG antibody (Dako) incubated on ice for 2 h. Following the last washings, 
HRP enzyme activity was visualized using ABTS. We analyzed sera of 214 RA patients and 
54 healthy subjects as controls. We transformed the absorbance on Fib Ci-Fib and Ca-Fib to 
arbitrary units per milliliter. We established the cut-off for a positive response as the mean 
plus two times the SD of the specific anti-CarP reactivity of the healthy controls. These assays 
were repeated three times showing the same data. 
F(ab´)2 preparation
Total IgG from two anti-CarP–positive and two control sera were isolated via a HiTrap 
protein A HP column (GE Healthcare) following the protocol for the column provided 
by the manufacturer. F(abʹ)2 fragments were generated from purified IgG samples 
using a F(abʹ)2 Preparation Kit (Thermo Scientific) following the protocol provided by 
the manufacturer. We have verified the molecular nature of the intact IgG and the F(abʹ)2 using 
Coomassie-stained SDS-PAGE gels. These F(abʹ)2 were used in ELISA, as described 
above, now using either HRP-labeled rabbit anti human IgG, IgA, IgMκ, λ-antibody 
(antilight chain) (Dako), or HRP-labeled rabbit antihuman IgG (Dako).
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Detection of ACPA by ELISA
Antibodies against citrullinated protein antigens (ACPA) were measured by the CCP2 
ELISA (Immunoscan RA Mark 2; Eurodiagnostica). Samples with a value above 25 U/mL 
were considered positive according to the manufacturer’s instructions. A small percentage 
of ACPA-positive RA patients may be outside the anti-CCP2 reactivity, and therefore 
both terms will be used to explicitly indicate what has been used in our analyses. ACPA 
reactivity toward Ci-FCS was detected using ELISA plates that were coated with Ci-FCS 
(50 μL per well 10 μg/mL) diluted with CB in the Nunc Maxisorp plates overnight at 4 
°C. The plates were washed in PT followed by blocking with 100 μL PBS/1%BSA solution 
at 37 °C for 1 h. Following washing, sera were incubated at a 1/50 dilution in 50 μL PTB 
and incubated at 37 °C for 1 h. After washing, human IgA and IgG were detected as 
described above.
Detection of anti-CarP antibodies by western blot
FCS, Ca-FCS, and Ci-FCS were loaded onto 10% SDS-polyacrylamide gels and transferred 
onto Hybond-C Extra membranes (Amersham). Blots were incubated in blocking 
buffer (3% ELK Milk/PBS/0.05% Tween) for 1 h at room temperature, following washing 
with PT. The blots were subsequently incubated with 2.5 mL 1:500 diluted serum in blocking 
buffer for 1.5 h at room temperature. The sera were either ACPA-positive anti-CarP–negative 
or ACPA-negative anti-CarP–positive as determined by
ELISA. After three washes with PT, blots were incubated with 5 mL HRP-labeled rabbit anti-
human IgG diluted in blocking buffer for 1 h at room temperature. Next, blots were washed 
and bound antibodies were visualized using enhanced chemiluminescence (Amersham).
Statistics of radiological progression
Association between anti-CarP antibodies positivity and radiographic progression was 
analyzed using the Statistical Package for the Social Sciences 17.0 as described earlier. 
P values below 0.05 were considered statistically significant. A multivariate normal regression 
analysis for longitudinal data were used with radiological score as response variable. 
This method analyses repeated measurements at once and takes advantage of the correlation 
between these measurements, which results in a more precise SE. Radiological scores were 
log-transformed to obtain a normal distribution. The rate of joint destruction over time was 
tested by an interaction of time with anti-CarP. The effect of time was assumed to be linear in 
the interaction term. The effect of time was entered as a factor in the model as well, allowing 













were included as correction variables in all analyses. In a separate analysis, the effect of 
anti-CarP antibodies was corrected for the effect of anti-CCP and rheumatoid factor.
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Anti-citrullinated protein antibodies (ACPA) play an important role in the diagnosis and 
prognosis of rheumatoid arthritis (RA). The anti-modified citrulline (AMC) (‘Senshu’) 
method is the most frequently used method to detect citrullinated proteins. Recently, we 
identified antibodies against carbamylated proteins (anti-CarP antibodies) and studied 
whether the ‘AMC-Senshu’ method and human antibodies could discriminate citrullinated 
and carbamylated proteins.
Methods
We analyzed the reactivity of the ‘AMC-Senshu’ method and human antibodies on western 
blots targeting citrullinated, carbamylated or non-modified fetal calf serum (FCS) and 
fibrinogen (Fib). The cross-reactivity of ACPA and anti-CarP antibodies in double positive 
sera were also examined via the inhibition assays and ACPA depletion columns.
Results
The ‘AMC-Senshu’ method strongly stained both citrullinated and carbamylated FCS and Fib 
but not the non-modified counterparts. There are sera which stained both citrullinated and 
carbamylated forms of Fib and sera stained only one form of modified Fib. In the inhibition 
assays, sera binding to Ca-Fib can be inhibited by Ci-Fib to various degrees whereas binding 
to Ci-Fib could only be inhibited by Ca-Fib to approximately 30%. After ACPA depletion, 
more than half of anti-CarP antibodies remained in the flow through in 5 out of 7 samples, 
confirming that also in double positive individuals two separate antibody families exist.
Conclusions
The ‘AMC-Senshu’ method can not differentiate citrullinated and carbamylated epitopes. 
However, human antibodies can partially differentiate between them. In light of the recently 
identified anti-CarP antibodies, the extent and nature of citrullination and carbamylation in 














Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease mainly affecting 
synovial joints. The disease process is characterized by joint damage and bone destruction and 
may lead to severe disability and increased mortality. Around 20 years ago, anti-citrullinated 
protein antibodies (ACPA) were discovered in RA patients and are now established as 
an important diagnostic and prognostic marker.[1] Although its role in the pathogenesis 
of RA is not yet fully elucidated, evidence on a possible pathologic role is accumulating. 
[2-7] Identifying citrullinated antigens recognized by ACPA is not only essential for a better 
understanding of RA but may also open a new window for early intervention. The assay used 
most frequently to identify citrullinated proteins is the anti-modified citrulline (AMC) assay. 
This assay is based on chemically adding ureido group adducts to citrulline residues followed 
by detection with a specific antibody developed by Dr. Senshu.[8] This assay has brought 
insight into the understanding of RA since it was used to show the presence of citrullinated 
proteins in the target tissues.[9-17] An advantage of the “AMC-Senshu” antibody is that it 
recognizes citrullinated epitopes irrespective of the neighboring amino acids. Recently, we 
and others described a novel family of autoantibodies in RA patients, anti-carbamylated 
protein (Anti-CarP) antibodies, which target carbamylated epitopes instead of citrullinated 
epitopes.[18,19] Since citrulline and homocitrulline are very similar, we wished to verify 
whether this method could distinguish between citrulline and homocitrulline as well as 
to determine to which extent human autoantibodies can differentiate between these two 
antigenic entities. To address this question, we studied whether the “AMC-Senshu” antibody 
and selected human sera can differentiate citrullinated and carbamylated proteins.
Methods
Generation of antigens
In brief, citrullinated fetal calf serum (Ci-FCS) and citrullinated fibrinogen (Ci-Fib) as well 
as carbamylated FCS (Ca-FCS) and carbamylated fibrinogen (Ca-Fib) were generated via 
incubation with either peptidylarginine deiminase 4 (Sigma) or potassium cyanate (Sigma) 
and confirmed by mass-spectrometry as described before.[18]
Autoantibody assays and inhibition assays
ELISA for the detection of anti-CarP Fib and anti-CarP FCS was performed as previously 
described.[18] Anti-CCP2 reactivity was detected using commercial CCP2 assays 
(Eurodiagnostica).[18] For the inhibition assys, four sera were incubated with Fib, Ci-Fib or 
Ca-Fib at 4°C overnight before detecting binding to Ci/Ca-Fib. 
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Coomassie blue staining and western blot (WB)
FCS, Ci-FCS, Ca-FCS, Fib, Ci-Fib and Ca-Fib were loaded with equal amounts onto 10% 
SDS-polyacrylamide gels and stained by SimplyBlue™ SafeStain staining (Life technologies) 
following the protocol from the manufacturer. The same gel was prepared and transferred 
onto Hybond-C Extra membranes (Amersham). 
Selected human sera and the “AMC-Senshu” antibody were used to stain the blots. Ci-Fib 
positive/Ca-Fib negative, Ca-Fib positive/Ci-Fib negative and double positive sera were 
selected from previously performed anti-CarP Fib ELISA’s. The protocol using these 3 sera 
to stain the Fib, Ci-Fib and Ca-Fib blots is the same as previously described.[18] Staining 
using the “AMC-Senshu” antibody (Millipore) followed the protocol in the kit. In brief, 
before applying the AMC antibody and its detection antibody, the blot was incubated with 
2,3-butanedione monoxime and antipyrine in strong acidic environment to form ureido 
group adducts.
ACPA depletion/purification column 
Biotinlylated CCP2 peptides or the arginine control were loaded onto 1ml HiTrap 
Streptavidin HP Columns (GE healthcare). One column containing the CCP2 arginine 
peptide was placed on top of two columns containing CCP2 peptides. After washing, ACPA/
anti-CarP double positive sera were applied to the columns. Following washing the column 
was eluted by pH 2.5, 0.1 M glycine-HCl. The eluted antibodies were neutralized by 1M 
Tris, pH 8. The starting material, flow through and elution were tested on anti-CarP FCS 
and CCP2 ELISA.
Results 
The “AMC-Senshu” method does not discriminate between 
citrullinated and carbamylated proteins
One gel was used to visualize equal loading of citrullinated, carbamylated or non-
modified FCS or Fib (Figure 1A). The other equally loaded gel was used for Western-
blotting and the resulting blot was used for the “AMC-Senshu” staining. Development of 
this blot revealed that both the citrullinated and the carbamylated forms of both FCS and 
Fib were strongly stained whereas the non-modified proteins did not reveal any staining 
(Figure 1B). These data indicate that the “AMC-Senshu” method identifies both citrulline 
and homocitrulline containing proteins and that it does not discriminate between 













Figure. 1 The “AMC-Senshu” method does not discriminate citrullinated and carbamylated 
antigens while human autoantibodies do. (A)  Coomassie blue staining showed equal loading of 
FCS, Ci-FCS, Ca-FCS, Fib, Ci-Fib and Ca-Fib. (B) The “AMC-Senshu” antibody used according to 
the protocol of the manufacturer did not recognize FCS and Fib, but strongly recognized Ci-FCS, 
Ca-FCS, Ci-Fib and Ca-Fib. (C) Three selected RA sera can recognize both Ci-Fib and Ca-Fib or 
only one of the modifications specifically.
Human autoantibodies can discriminate between citrullinated and 
carbamylated antigens
To analyze whether human antibodies can actually discriminate between citrullinated and 
carbamylated proteins we applied sera of selected RA patients to stain blots containing 
Ci-Fib, Ca-Fib and Fib. Staining similar western blots with selected human sera revealed that 
sera positive for ACPA and anti-CarP stained both citrullinated (Ci) and carbamylated (Ca) 
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forms of Fib, whereas, single positive sera stained only one form of modified Fib (Fig 1C). 
These data indicate that although the ‘AMC-Senshu’ method does not discriminate between 
these two modifications, human sera of RA patients are able to distinguish. 
In the sera analyzed in the inhibition assays, binding to Ca-Fib can be inhibited by Ci-Fib to 
various degrees, whereas binding to Ci-Fib could be inhibited by Ca-Fib to approximately 
30% (Fig 2A, 2B). These data indicate that part, but not all ACPA and anti-CarP antibodies 
are cross-reactive.
Figure 2 Anti-CarP antibodies and ACPA represent two families of autoantibodies 
(A) Inhibition studies on sera double positive for ACPA and anti-CarP antibodies. Fib does not 
inhibit sera binding to Ca-Fib. Ci-Fib can partially inhibit sera binding to Ca-Fib whereas Ca-Fib 
can completely inhibit binding to itself. (B) Fib does not inhibit sera binding to Ci-Fib whereas 
Ci-Fib can inhibit more than 97% of binding to itself. Ca-Fib can only inhibit less than 30% of 
sera binding to Ci-Fib. (C) After ACPA depletion using CCP2 loaded columns, more than 98% 
of ACPA were depleted from the sera while more than 50% of anti-CarP antibodies remained in 













We have shown previously that anti-CarP antibodies can be found in a subgroup of ACPA 
negative individuals but that the majority of anti-CarP positive individuals are also ACPA 
positive. We have shown above that in double positive individuals two separate reactivities 
exist by performing pre-incubation experiments. We have now verified this aspect further 
by studying whether in double positive individuals anti-CarP reactivity would remain after 
removal of ACPA using CCP2 columns. After ACPA depletion, more than 98% of ACPA 
in the sera were depleted (Figure 2C) while more than half of the anti-CarP antibodies 
remained in the flow through in 5 out of 7 samples (Figure 2C). Together, these data confirm 
that two separate autoantibody systems exist directed against citrullinated or carbamylated 
antigens. Nonetheless, in double positive individuals, there appears to be a cross-reactive 
portion as well as two mono-specific portions.
Discussion
To answer the question whether the “AMC-Senshu” method and human autoantibodies 
can distinguish citrullination from carbamylation, we performed western blots using 
the “AMC-Senshu” system and human sera. We found the “AMC-Senshu” method can not 
differentiate citrullination and carbamylation. Our finding is in line with a previous report 
suggesting that the AMC-Senshu method also detects homocitrulline.[20,21] 
Importantly, our experiments showed that certain human sera can recognize either 
citrullinated or carbamylated proteins but not both. Since anti-CarP antibodies and ACPA 
are often found together we analyzed whether in double positive individuals two separate 
reactivities co-exist or that this only reflects cross-reactivity. By depletion of ACPA, we 
showed that double positive samples harbor anti-citrullinated epitope-specific antibodies, 
anti-carbamylated epitopes specific antibodies as well as cross-reactive antibodies.
In this study, we found that the “AMC-Senshu” method can recognize both citrullinated 
and carbamylated proteins. This finding does not argue against the notion that citrullinated 
proteins are present in the synovial fluid and tissues. Especially since in a number of studies, 
citrullinated proteins were first detected by the “AMC-Senshu” method and then further 
confirmed by mass-spectrometry fingerprinting.[9-12] However, our findings highlight that 
in these studies next to citrullinated proteins also carbamylated proteins may have been 
detected. In light of the recently identified anti-CarP antibodies, the extent and nature of 
citrullination and carbamylation in the joint should be re-evaluated.
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Recently, we discovered a new autoantibody system in rheumatoid arthritis (RA): 
anti–carbamylated protein (anti-CarP) antibodies. These antibodies have value in predicting 
joint destruction; however, it is not clear whether they are present before the diagnosis of 
RA and whether they have value as predictors of RA development. Therefore, we studied 
whether anti-CarP antibodies are present in patients with arthralgia and whether their 
presence is associated with the development of RA.
Methods
Sera from 340 arthralgia patients who did not have clinical signs of arthritis but who were 
positive for IgM rheumatoid factor (IgM-RF) and/or anti–cyclic citrullinated peptide 2 
(anti–CCP-2) and 32 healthy controls were tested for anti-CarP IgG antibodies. Of the 
patients with arthralgia, 111 were IgM-RF positive/anti–CCP-2 antibody negative and 229 
were anti–CCP-2 antibody positive. Patients were observed for the development of RA 
(based on the 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria) during a median followup period of 36 months. 
Cox proportional hazards regression analysis was performed to compare the risk of 
developing RA between arthralgia patients who were positive for anti-CarP antibodies and 
those who were negative for anti-CarP antibodies during followup.
Results
Anti-CarP antibodies were present in the sera of 39% of the patients. One hundred 
twenty patients developed RA, after a median of 12 months (interquartile range [IQR] 
6–24). The presence of anti-CarP antibodies was associated with the development 
of RA in the entire  arthralgia cohort after correction for RF and anti–CCP-2 
antibody status (hazard ratio 1.56 [95% confidence interval 1.06–2.29], p = 0.023), as 
well as in the anti–CCP-2 antibody–positive subgroup (odds ratio 2.231 [95% confidence 
interval 1.31–3.79], p = 0.003).
Conclusion
Anti-CarP antibodies are present in patients with arthralgia, and their presence predicts 














Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder. The disease 
process often causes the destruction of joints, which can lead to considerable disability. 
Autoantibodies such as rheumatoid factor (RF) and anti–citrullinated protein antibodies 
(ACPAs) are important diagnostic markers for RA and may also contribute to 
pathogenesis (1). ACPA-positive patients with RA have more radiologic damage and 
a lower chance of attaining disease remission without disease-modifying antirheumatic 
drugs (DMARDs) than ACPA-negative patients with RA (2–5). In pre-RA states such as 
arthralgia and undifferentiated arthritis, ACPA and RF are predictive factors for future 
progression to RA (6, 7).
Recently, we discovered another autoantibody system present in RA patients, which we 
designated as anti–carbamylated protein antibodies (anti-CarP) (8). These antibodies target 
carbamylated proteins rather than citrullinated proteins. Carbamylation is a process in which 
lysines are converted into homocitrullines under the influence of cyanate. Homocitrulline is 
an amino acid that highly resembles citrulline. Cyanate can be formed in low concentrations 
from urea under physiologic conditions or it can originate from the environment, e.g., from 
car fumes. In inflammatory conditions, it can be formed from thiocyanate that has been 
catalyzed by myeloperoxidase released by, e.g., activated neutrophils. Whether anti-CarP 
antibodies are directly involved in the pathogenesis of RA is currently unknown.
In a previous article, we reported that anti-CarP antibodies are present in both ACPA-positive 
patients (74%) and ACPA-negative patients (16%) with RA (8). In RA patients, they are 
a prognostic factor for a higher likelihood of joint destruction independent of ACPA status. 
However, at present it is unknown whether they exist in patients who have arthralgia but 
do not meet criteria for RA and whether they could have predictive value in those patients. 
Therefore, we tested for the presence of anti-CarP antibodies and studied the association 
between anti-CarP antibody status and levels and the risk of developing RA in a cohort 
of patients with arthralgia who were positive for ACPA (determined based on levels of 
anti–cyclic citrullinated peptide 2 [anti–CCP-2] and/or RF).
Patients and methods
Study population
The inclusion procedure was as previously described (6). Briefly, 340 Caucasian patients 
from the Amsterdam area, who did not have arthritis but who were positive for anti–CCP-2 
antibody and/or IgM-RF and had a history of arthralgia, were included. Absence of arthritis 
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was confirmed by physical examination of 44 joints by a trained physician and a senior 
rheumatologist (DvS) (9). Medical history, details of joint symptoms, and the number of 
tender joints were recorded (10). Patients who had arthritis as determined by chart review 
or baseline physical examination, were negative for anti-CCP antibodies and IgM-RF on 
second analysis, had previously been treated with DMARDs, or had recently been treated 
with glucocorticoids (within the last 3 months) were excluded. Patients were followed up 
semiannually in the first year and yearly thereafter for the development of RA according to 
the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism 
(EULAR) classification criteria (1). Additional visits were scheduled if RA developed. 
Healthy control sera were collected from 32 Caucasian residents of the Leiden area. 
Protocols were approved by the local ethics committee, and informed consent was obtained 
from all subjects.
Anti-CarP IgG antibody enzyme-linked immunosorbent assay (ELISA)
Anti-CarP IgG antibodies in the sera from patients and controls were detected by ELISA 
as previously described (8). Briefly, Nunc MaxiSorp plates (Thermo Scientific) were coated 
with 10 μg/ml fetal calf serum (FCS; Bodinco) and carbamylated (Ca)–FCS at 4°C overnight. 
The plates were blocked with 1% bovine serum albumin (Sigma) at 4°C for 6 hours, followed 
by incubation overnight with 1:50 diluted sera on ice. Bound antibodies were detected 
by incubation for 4 hours with horseradish peroxidase–conjugated rabbit anti-human 
IgG (Dako) on ice and subsequently visualized with ABTS. Absorbance was measured at 
415 nm and transformed to arbitrary units (AU) per milliliter using the titration curve of 
a serum pool from 3 anti-CarP antibody–positive samples. The background signal of 
FCS was subtracted from the signal of Ca-FCS to analyze the specific anti-CarP antibody 
reactivity. Sera with a level of >202 AU/ml were considered positive for anti-CarP antibodies. 
This cutoff was equivalent to 2 SD above the mean in the healthy controls.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 software. Chi-square test, 
t-test for independent samples, binary logistic regression, and Cox proportional hazards 
regression analysis were used to compare anti-CarP antibody–positive and anti-CarP 
antibody–negative groups in the whole population and in the anti–CCP-2 antibody–positive 
and –negative populations. Binary logistic regression analysis was performed to analyze 
the association between the anti-CarP IgG antibody level and the risk of developing RA 
in the anti-CarP IgG antibody–positive subgroup. Hazard ratios (HRs), odds ratios (ORs), 















The 340 patients with arthralgia included in this study were followed up for a median of 
36 months (interquartile range [IQR] 20–52). Baseline characteristics are listed in Table 1. 
After a median of 12 months (IQR 6–24), 120 patients (35%) developed RA according to 
the 2010 ACR/EULAR criteria. At the time of diagnosis of RA, these patients had a median 
swollen joint count of 3 (IQR 2–5). Of the remaining 220 patients, 9 patients developed 
undifferentiated arthritis.
Table 1. Baseline characteristics of the 340 patients with arthralgia*
Age, mean ± SD years 49 ± 11
Sex, no. (%) female 256 (75)
Duration of symptoms, median (IQR) months 12 (8–36)
No. of reported painful joints, median (IQR) 3 (1–8)
Tender joint count, median (IQR) 0 (0–2)
IgM-RF positive, no (%) 209 (62)
Anti–CCP-2 positive, no (%) 229 (67)
Followup time, median (IQR) months 36 (20–52)
*IQR = interquartile range; IgM-RF = IgM rheumatoid factor; anti–CCP-2 = anti–cyclic  
citrullinated peptide 2.
One hundred thirty-three patients (39%) were positive for anti-CarP antibodies (Figure 1). 
Of these patients, 68 (51%) developed RA, whereas 52 patients (25%) who were negative 
for anti-CarP antibodies developed RA. Anti-CarP antibody positivity was significantly 
associated with RA development (p < 0.001). In the group of arthralgia patients positive for 
anti-CarP antibodies, the levels of anti-CarP IgG antibodies were not associated with the risk 
of developing RA (p = 0.215).
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Figure 1. Presence of anti–carbamylated protein (anti-CarP) antibodies in patients with 
arthralgia and in controls. Anti-CarP IgG antibody positivity was found in 6% of healthy 
controls and 39% of patients with arthralgia. Each data point represents a single subject. 











Among 111 anti–CCP-2 antibody–negative patients, 17 (15%) were positive for 
anti-CarP antibodies, while among 229 anti–CCP-2 antibody–positive patients, 116 (51%) 
were positive for anti-CarP antibodies (p < 0.001). Given this association, we next studied 
whether anti-CarP antibody positivity is also an independent predictor of RA development 
in the anti–CCP-2 antibody–positive and anti–CCP-2 antibody–negative subgroups. In 
the anti–CCP-2 antibody–positive subgroup, 68 patients (58%) who were positive for anti-
CarP antibodies developed RA, while only 44 patients (40%) who were negative for anti-
CarP antibodies developed RA. The association between anti-CarP antibodies and RA 
remained significant (OR 2.231 [95% CI 1.31–3.79], p = 0.003), while this was not the case 
in the anti–CCP-2 antibody–negative subgroup (OR 1.12 [95% CI 0.22–5.63], p = 0.891).
Anti-CarP antibody–positive patients also displayed higher anti-CCP antibody levels 
as compared to anti-CarP antibody–negative patients (p < 0.001). Similarly, after 
correction for anti-CCP antibody levels, anti-CarP antibody positivity still increased 
the risk of developing RA in anti-CCP antibody–positive arthralgia patients (p = 0.032). 
Unlike anti–CCP-2 antibodies, the presence of anti-CarP antibodies was 
not correlated with IgM-RF (p = 0.391).
Taking into account the differences in followup time, Cox proportional hazards regression 
analysis revealed a statistically significant association between anti-CarP antibody status 
and the risk of developing RA. This indicates that anti-CarP antibody–positive patients 
not only were more likely to develop RA, but also were more likely to develop RA within 













remained significant after correction for anti–CCP-2 antibody status and IgM-RF status 
(HR 1.56 [95% CI 1.06–2.29], p = 0.023) (Figure 2) or after correction for anti–CCP-2 
antibody levels and IgM-RF status (p < 0,001).
Figure 2 Association of presence of anti–carbamylated protein (anti-CarP) antibodies in 
arthralgia patients with future development of rheumatoid arthritis (RA). Anti-CarP IgG 
antibodies are associated with a higher risk of developing RA after correction for anti–cyclic 
citrullinated peptide 2 antibody and rheumatoid factor status (hazard ratio 1.56 [95% confidence 
interval 1,06–2,29], p = 0,023).
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Although arthralgia patients often have a benign disease course, in a certain subset of 
these patients the condition may progress to RA. Identifying this subset at an early stage 
may be beneficial because intervention at this stage might prevent the development of RA. 
As an established biomarker, the presence of ACPA increases the risk of developing 
arthritis in patients with arthralgia. Still, the condition progresses to arthritis in only 27% 
of all ACPA-positive patients with arthralgia after 1 year of followup (6). In the present 
study we investigated whether anti-CarP antibodies are present in arthralgia patients 
and whether they are an additional risk factor for RA in these patients. We demonstrated 
that anti-CarP antibodies are present in arthralgia patients and that they are associated 
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with a higher risk of developing RA independent of ACPA and IgM-RF status. Within 
the anti–CCP-2 antibody–negative subgroup, we did not observe a significant 
association between anti-CarP antibodies and RA, possibly due to the low number of 
RA cases in this group.
Limited by the nature of the cohort, we were unable to address the question of whether 
anti-CarP antibodies can predict the development of RA in arthralgia patients who are 
negative for anti–CCP-2 antibodies and RF. Another limitation was the 3-year median 
followup time, which is relatively short and may have affected the percentage of patients 
developing RA. However, we observed that with increasing followup time the percentage 
of patients with arthralgia who develop RA decreases. Therefore, we believe that this effect 
will be limited. A further concern could be that these patients might have subclinical 
arthritis at baseline, undetected by physical examination. However, we have previously 
seen that the frequency of pathology as determined on ultrasound was very low in this 
population and moreover, that ultrasound was not superior to physical examination in 
the prediction of RA (11).
Our findings suggest that not only ACPA positivity, but also the presence of anti-CarP 
antibodies, can have clinical value in the prediction of RA in patients with arthralgia. 
Additionally, the presence of anti-CarP antibodies in persons at risk of developing RA 
provides a rationale for further studies on their potential pathogenetic properties. Although 
the presence of anti-CarP antibodies is associated with the risk of developing RA in 
ACPA-positive arthralgia patients, we previously did not obtain evidence that their presence 
is associated with radiologic progression in ACPA-positive patients with RA; such an 
association was only found in ACPA-negative RA patients (8). The reasons for these findings 
are not yet known and further replication is required; however, these results do resemble 
observations made in studies on ACPA fine specificity (12–14). The ACPA recognition 
profile does not correlate with radiologic progression in ACPA-positive RA (12), but 
the number of citrullinated epitopes recognized by ACPA is associated with RA development 
in patients who have arthralgia or undifferentiated arthritis (13, 14). Apparently, in the first 
stage of disease, the number of epitopes recognized and isotypes used by ACPA (5), as well as 
the number of autoantibodies present, are determining factors for disease progression. They 
matter less, however, when a certain threshold has been passed, possibly explaining the lack 
of association in established RA.
Despite the similarity between the presence of anti-CarP antibodies and the broadening 
of ACPA fine specificities with respect to prediction of RA, anti-CarP antibodies are not 
a fine specificity of ACPA, since they are largely non–cross-reactive with defined (homo)













as described herein is still present after correction for the effect of anti–CCP-2 antibodies, as 
would be expected for two independent autoantibody systems.
Taken together, our data reveal that anti-CarP antibodies are present before RA becomes 
clinically apparent, since they can be found in patients who have arthralgia without 
signs of arthritis. Furthermore, their presence in this population is associated with 
the development of RA.
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The presence of anti-citrullinated protein antibodies (ACPA) and IgM-rheumatoid 
factor (IgM-RF) years before the clinical diagnosis of rheumatoid arthritis (RA) suggests 
they are possibly involved in the pathogenic process underlying RA. In this study, we 
analysed whether anti-carbamylated protein (anti-CarP) antibodies, a novel autoantibody 
system against carbamylated proteins, can also be detected in healthy individuals before 
they developed RA.
Methods
Multiple sera from asymptomatic blood donors prior to the onset of their RA symptoms and 
sera from age-matched and sex-matched controls were tested for the presence of antibodies 
directed against carbamylated-fetal calf serum (Ca-FCS), carbamylated-fibrinogen (Ca-Fib), 
cyclic citrullinated-peptide 2 and IgM-RF.
Results
Anti-Ca-FCS and anti-Ca-Fib antibodies were each present in 27% and 38% of the last 
serum samples of blood donors prior to the diagnosis of RA. Both anti-Ca-FCS and 
anti-Ca-Fib antibodies could be detected many years before the onset of RA. Anti-CarP 
antibodies as well as ACPA are, on average, detected earlier than IgM-RF.
Conclusions
In addition to ACPA and IgM-RF, also the newly identified anti-CarP antibodies appear 














Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting the synovial 
joints.[1] Early and aggressive intervention in individuals who are developing RA may 
prevent irreversible bone loss and induce early remission.[2] Identification of individuals 
who could benefit most from such an intervention is a challenge, but the presence of 
autoantibodies could be a useful marker. Besides IgM-rheumatoid factor (IgM-RF) also 
anti-citrullinated protein antibodies (ACPA) are implicated in the disease progression 
of RA[3] and are now included in the 2010 American College of Rheumatology (ACR)/
The European League Against Rheumatism criteria for RA.[4] Both ACPA and RF can be 
detected in serum many years prior to the onset of symptoms.[5–7] Recently, we identified 
a novel autoantibody family consisting of anti-carbamylated protein (anti-CarP) antibodies.
[8] Carbamylation is a post-translational modification in which lysines are chemically 
converted to homocitrullines.[9] The presence of anti-CarP antibodies is associated with 
more radiological progression over time in ACPA-negative RA patients [8] and with 
the conversion from arthralgia to RA.[10]
In this study, we have analysed whether anti-CarP antibodies are already present in healthy 
individuals before the diagnosis of RA and how the appearance of anti-CarP antibodies 
relates to the appearance of ACPA and IgM-RF.
Methods
Study population
Sera from 79 asymptomatic blood donors (48 women), with a mean age at diagnosis 
of 51 years, collected before they developed RA as well as from 141 age-matched and 
sex-matched controls were obtained as described before.[6,11]
In brief, sera of patients who fulfilled the ACR 1987 criteria for RA12 obtained before 
the diagnosis of RA were collected from the Sanquin Blood Bank. A median of 5 
(IQR 4–6) sequential sera from blood donors obtained at 1–6-year intervals were available for 
analysis. The clinical information of patients was retrieved from medical records. Sera of 141 
sex-matched and age-matched healthy blood donors collected in the same period as 
the samples of the individuals who developed RA were also collected from the Sanquin 
Blood Bank. All patients and controls are Caucasian. Informed consent was obtained from 
the participating RA patients. The study was approved by the Slotervaartziekenhuis and 
Reade ethical review board, Amsterdam, The Netherlands, with the condition, however, that 
we were not allowed to contact the control donors for reasons of privacy.
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Antibody detection
Sera collected on the last visit prior to the diagnosis of RA (median time before diagnosis: 
1,4 years, IQR: 0,8–1,8 years) were measured for the presence of anti-carbamylated-
fetal calf serum (anti-Ca-FCS), anti-carbamylated-fibrinogen (anti-Ca-Fib), anti-cyclic 
citrullinated-peptide 2 (anti-CCP2) antibodies and IgM-RF. Next, of individuals positive for 
at least one autoantibody, all consecutive samples were analysed.
Anti-Ca-FCS and anti-Ca-Fib antibodies were detected by ELISA as described before.8 
The anti-CCP2 ELISA (Euro-Diagnostica) was performed following the manufacturer’s 
instructions. The IgM-RF ELISA was performed as previously described.[6,11] The cut-off 
for the anti-Ca-FCS and anti-Ca-Fib ELISA was set as the mean plus two times the SD of 
healthy controls.
Statistics
Mann–Whitney U test (one-tailed) was performed to compare the time points before 
the diagnosis of RA when the different autoantibodies were detectable for the first time.
Results
The characteristics of the 79 asymptomatic blood donors who developed RA later used 
in this study have been described previously.[6,11] Sera collected on the last visit prior to 
the diagnosis of RA were analysed for the presence of anti-Ca-FCS, anti-Ca-Fib, anti-CCP2 
antibodies and IgM-RF. At the time of diagnosis, the patients reported a 0.9-year median 
duration of joint symptoms. Twenty-one (26.6%) donors were positive for anti-Ca-FCS 
antibodies, 30 (38,0%) for anti-Ca-Fib antibodies, 33 (41.8%) for anti-CCP2 antibodies and 
19 (24,0%) for IgM-RF (figure 1A). The numbers of single-positive, double–positive and 













Figure 1 Anti-carbamylated protein (Anti-CarP) antibodies are present in asymptomatic 
blood donors before they developed rheumatoid arthritis (RA) (A) Anti-carbamylated-
fetal calf serum (anti-Ca-FCS), anti-carbamylated-fibrinogen (anti-Ca-Fib), anti-cyclic 
citrullinated-peptide 2 (anti-CCP2) antibodies and IgM-rheumatoid factor (IgM-RF) 
are each present in 27%, 38%, 42% and 24% of the serum samples taken from donors 
most recently before their diagnosis of RA. (B) The absolute numbers of single-positive, 
double-positive, triple-positive and autoantibody-negative donors are listed. ACPA, 
anti-citrullinated protein antibodies.
anti-CarP: 5
ACPA: 6 IgM-RF: 2
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Analysis of the longitudinal samples from the donors who were positive for at least one 
autoantibody at the last visit prior to the diagnosis of RA revealed that similar to ACPA 
and IgM-RF also anti-Ca-FCS and anti-Ca-Fib antibodies can be detected years before the 
diagnosis of RA (figure 2A). There is a steady increase in the percentage of individuals with 
a positive antibody status for each of the autoantibodies studied over time. The moment 
when IgM-RF, anti-Ca-FCS, anti-Ca-Fib and anti-CCP2 antibodies were detectable for 
the first time were 10, 14, 14 and 14 years before diagnosis, respectively (figure 2A,B). 
These are the time points when the first samples of these donors were collected. The median 
(IQR) of time points when anti-CCP2, anti-Ca-FCS, anti-Ca-Fib antibodies and IgM-RF 
were detectable were 6 (3–10), 5 (3–7), 7 (4–10) and 2 (1–5) years before the diagnosis 
(figure 2B). Comparing the time points when each of these three autoantibody families could 
be detected for the first time in this cohort revealed that anti-CarP and anti-CCP2 antibodies 
appeared around the same time, while IgM-RF appeared significantly later (figure 2B). 
We observed an increase in the number of autoantibody reactivities present in the samples 
over time. Six years before the diagnosis, more than 50% of the autoantibody-positive donors 
harboured only one autoantibody family, whereas at least 30% of the autoantibody-positive 
donors displayed all three autoantibody families within 4 years before diagnosis (figure 2C).
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Figure 2 The development of autoantibodies over time (A) The percentage of autoantibody-
positive donors increases over time. (B) The first time point that IgM-rheumatoid factor (IgM-RF) 
appeared is significantly later than anti-cyclic citrullinated-peptide 2 (anti-CCP2) and anti-CarP 
antibodies reacting with Ca-FCS and with Ca-Fib. (C) The percentages of blood bank donors that 
harbour 0, 1, 2 or 3 autoantibody families are calculated. The number of autoantibody-positive 































































































Next to positivity, the levels of autoantibodies increased within the majority of followed 
blood donors. The levels of anti-CCP2, anti-Ca-FCS, anti-Ca-Fib antibodies and IgM-RF 
levels each increased in 83% (33/40), 78% (31/40), 53% (21/40) and 85% (34/40) of donors. 
The median levels of all autoantibodies start to increase around 5–7 years before 
the diagnosis or RA (figure 3).
Figure 3 The median levels of autoantibodies increase over time Median level of each 
autoantibody was calculated for every year. The median levels at time point 0 of all autoantibodies 
were set at 100%. The median levels of other time points were presented as the percentage of 
the median level of time point 0. The number below the x-axis is the number of all available 
samples at the given time points. Time points before 10 years were not shown since 
the total sample number is too low. (A) Anti-Ca-FCS, (B) Anti-Ca-Fib, (C) anti-cyclic 
citrullinated-peptide 2 (anti-CCP2) and (D) IgM-rheumatoid factor (IgM-RF).
available samples at the given time points. Time points before 10 years were not shown since the total 
sample number is too low. (A) Anti-Ca-FCS, (B) Anti-Ca-Fib, (C) anti-cyclic citrullinated-peptide 2 (anti-
CCP2) and (D) IgM-rheumatoid factor (IgM-RF).
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Discussion
ACPA and IgM-RF have been reported to be present many years before the onset of 
the clinical symptoms of RA.[5–7] Here, we observed that also anti-CarP antibodies are 
present before the onset of the clinical symptoms of RA. The moment of first appearance 
of anti-CarP antibodies is comparable with ACPA and earlier than IgM-RF. Levels of each 
of these autoantibodies appear to increase with similar kinetics. From the current data, 
it is not possible to conclude on the relative contribution of each of these antibodies on 
the pathogenesis of RA.
Incidences and levels of anti-CCP2 antibodies and IgM-RF in this report are slightly different 
from previous reports [6,11] on this cohort, because of a different approach in patient 
follow-up. In the present report, only donors who had a positive test in the last sample 
before the diagnosis of RA were followed, while previous reports mentioned cumulative 
percentages of positivity in all samples.
Homocitrulline is rather similar to citrulline but is one methylene group longer. Nonetheless, 
anti-CarP antibodies and ACPA appear by and large as two different autoantibody systems 
as anti-CarP antibodies are present in both ACPA-positive and ACPA-negative RA patients. 
In addition, inhibition studies, ACPA depletion studies and western blot analyses have 
revealed that next to a ‘cross-reactive’ component both antibody families have components 
recognising only citrulline-containing or homocitrulline-containing proteins/peptides.
[8,13] Compared with anti-Ca-FCS antibodies, anti-Ca-Fib antibodies may have more 
cross-reactivity to citrullinated proteins.[13] In this study, we observed five blood bank 
donors who were ACPA negative but positive for either anti-Ca-FCS [1] or anti-Ca-Fib 
antibodies [4]. We also observed six donors who were only positive for ACPA. Furthermore, 
ACPA and anti-CarP antibodies do not appear at the same moment in individuals as in 
26 double-positive donors, 13 donors developed anti-CarP antibodies first, 16 donors 
developed both at the same time and 6 donors developed ACPA first. Collectively these 
observations strengthen the concept that next to a cross-reactive component also 
non-cross-reactive antibodies exist. Because of the limited sample size of 79 individuals, 
replication studies in comparable cohorts are warranted.
Since autoantibodies can be detected many years before the onset of clinical symptoms, it 
is tempting to speculate that these antibodies may contribute to the pathogenesis of RA, 
for instance, by inducing osteoclastogenesis, tumour necrosis factor (TNF)-α secretion by 
macrophages or complement activation.[14–16] Our finding that anti-CarP antibodies can 
be present years before diagnosis adds another source of antibodies, which can potentially 
contribute to RA pathogenesis. Several genetic and environmental factors, such as shared 













as recently reviewed.[17] It would be interesting to know whether similar risk factors also 
predispose to anti-CarP antibodies.
The assays used to detect ACPA, anti-CarP antibodies and IgM-RF may differ in definition 
of cut-off and sensitivity, potentially limiting the comparability. Interestingly, IgM-RF 
seems to occur pathogenically subsequent to ACPA or anti-CarP antibodies. Observations 
made in American-Indian RA patients and their first-degree relatives may support this 
hypothesis.[18] These studies revealed that although either anti-CCP antibodies or IgM-RF 
can be found in both patients and their healthy first-degree relatives, the combination of 
both anti-CCP and RF is predominantly found in the RA patients. This supports the notion 
that ACPA and anti-CarP antibodies may initiate the primary target recognition but that 
amplification of IgM-RF is important for progression towards clinical RA, for example, by 
enhancing complement activation.[16,19,20]
In conclusion, we discovered that anti-CarP antibodies can be present in healthy blood 
donors many years before the development of clinical symptoms of RA.
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Anti-citrullinated protein antibodies (ACPA) have a low prevalence in juvenile idiopathic 
arthritis (JIA) patients. Recently, autoantibodies recognizing carbamylated proteins 
(anti-CarP) were observed in rheumatoid arthritis (RA) patients and were reported to 
be associated with a more severe clinical course in ACPA negative RA. We investigated 
the presence of anti-CarP antibodies in JIA patients and their relation to ACPA and 
IgM-rheumatoid factor (IgM-RF).
Methods
Cross-sectional samples of 234 JIA patients and 107 age-matched controls were analyzed for 
the presence of ACPA, IgM-RF and anti-CarP antibodies against carbamylated Fetal Calf 
Serum (FCS) or carbamylated Fibrinogen (Fib). The samples were obtained from patients in 
all different categories of JIA. Cut-off for positivity of anti-CarP antibodies was determined 
as the mean plus two times standard deviation of levels in sera of healthy controls.
Results
Anti-CarP FCS antibodies were present in 8,1% (19/234) of all JIA patients versus 
4,7% (5/107) of the controls. Anti-CarP FCS antibodies were predominantly present in 
IgM-RF positive polyarticular JIA patients (42,1%, p<0.0001 vs other JIA categories). 
A similar observation was made using anti-CarP Fib antibodies.
Conclusions
Anti-CarP antibodies can be detected in sera of JIA-patients, especially in the polyarticular 














Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic arthritides that 
starts before the age of 16. Different categories according to ILAR criteria are discerned [1] 
and the diagnosis is made clinically after exclusion of other causes of arthritis. Prognosis 
is currently largely unpredictable, except for rheumatoid factor (RF)-positive individuals. 
Reaching sustained remission is still scarce [2] although treatment options have improved 
with biologicals [3], resulting in better outcome.[4]  Research to identify markers predicting 
disease flares is ongoing,[5-7] but markers that predict severe disease are currently lacking. 
The discovery of anti-citrullinated protein antibodies (ACPA), often detected using 
assays based on cyclic-citrullinated peptides (CCP), has contributed substantially to 
the understanding of rheumatoid arthritis (RA).[8] The presence of ACPA is now part of the 
2010 EULAR/ACR criteria for RA. ACPA-positive RA patients have generally more severe 
disease courses with increased joint destruction.[9] Incidence rates for ACPA-positivity, 
usually detected by a CCP-assay, in JIA are low (2-5%).[10-13] The presence of ACPA in 
JIA is merely confined to the polyarticular IgM-RF positive JIA category that resembles RA. 
Recently, anti-carbamylated protein antibodies (anti-CarP) were described as a novel 
serological marker.[14-16] These antibodies are directed against proteins that have been 
modified by a post-translational modification named carbamylation. The physiological 
process of carbamylation increases during inflammation. In carbamylated proteins 
lysines are converted into homocitrullines. Anti-CarP antibodies were detected in 
sera of approximately 45% of RA patients and importantly in sera of 16-20% ACPA-
negative RA patients, in comparison to less than 3% in healthy controls.[15, 17, 18] 
Within the ACPA-negative patients the presence of anti-CarP antibodies was associated with 
more severe radiographic progression.[15] Therefore anti-CarP antibodies could serve as 
a new prognostic marker in ACPA-negative RA patients[19] Since the majority of JIA 
patients are ACPA-negative we analyzed whether anti-CarP antibodies can be detected 




JIA patients from three Dutch sources were included. The first group (n=33) consisted 
of patients participating in the BeSt for Kids trial, (NTR 1574) a treatment strategy study 
enrolling JIA patients. The second group (n=48) contained patients in early years of disease 
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participating a retrospective study described by Albers et al.[20] The third cohort (n=153) 
comprised participants of the Arthritis and Biologicals in Children (ABC) Register, an 
ongoing prospective observational study initiated in 1999, that aims to include all Dutch 
JIA patients treated with biologicals.[21] Healthy controls (n=107, mean age 11 years, range 
2-20 years) were anonymous pediatric donors of allogeneic hematopoietic stem-cell grafts. 
Written informed consent was obtained from all patients and controls. Patients’ disease 
characteristics and part of laboratory data (IgM-RF, ANA) were collected from patient 
files. Blood collection and storage are comparable among different cohorts. Median disease 
duration of the 234 JIA patients at the time of serum collection was 2,3 years (IQR 0,7-6,8) 
(Table 1). All International League against Rheumatism JIA categories were included with 
polyarticular JIA over-represented.[1, 22]  
Table 1 Disease characteristics of 234 juvenile idiopathic arthritis (JIA) patients
Characteristics Number
Gender m/f (%f) 76/158 (67,5%)
Median age (years) (IQR) 12.1 (8,4–16,2)
Median disease duration (IQR) 2.3 (0,7–6,8)
Median age at JIA onset (IQR) 8.8 (3,4–12,4)
ANA-positive at disease onset 64 (27,4%)
Systemic JIA 35 (15,0%)
Polyarticular JIA RF-negative 90 (38,5%)
Polyarticular JIA RF-positive 19 (8,1%)
Oligo-articular JIA extended 41 (17,5%)
Oligo-articular JIA persistent 18 (7,7%)
Juvenile psoriatic arthritis 24 (10,3%)
Enthesitis-related arthritis 5 (2,1%)
Undifferentiated 2 (0,8%)
ANA, anti-nuclear antibodies; RF, rheumatoid factor.
The correlation between anti-CarP antibodies and time in active disease as a measure of 
severity was investigated in the second cohort. The correlation between anti-CarP antibodies 
and ACRpedi30 response [23] (at least 30% improvement from baseline in 3 of 6 variables 
in the core set, with no more than 1 of the remaining variables worsening by >30%. Core set 
variables are 1) physician global assessment of disease activity; 2) parent/patient assessment 
of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) 
number of joints with limited range of motion; and 6) erythrocyte sedimentation rate) after 













Detection of anti-CarP antibodies, anti-CCP antibodies,  
ANA and IgM-RF
Anti-CarP antibodies were measured by ELISA using carbamylated Fetal Calfs-Serum 
(Ca-FCS) and human Fibrinogen (Ca-Fib) as antigens as described previously.[15] ACPA 
were measured using the CCP2 ELISA (Immunoscan RA Mark 2; Eurodiagnostica). Samples 
with a value above 25 units/ml were considered positive according to the manufacturer’s 
instructions. IgM-RF and ANA levels were determined at disease onset as part of routine 
patient care. For measuring ANA levels most Dutch hospitals use a standard indirect 
immunofluorescence technique on ethanol fixed HEp-2 cells and IgM-RF levels are usually 
determined by ELISA. 
Statistical Analysis 
Statistical analyses were performed with SPSS 17,0. Fisher’s exact test was used for testing 
the significance of differences between the percentages anti-CarP-positive and -negative 
patients. Pearson’s chi square and student’s t-test were used for identifying differences in 
time–in-active-disease [20] and ACRpedi30 response [23] between anti-CarP-positive 
and negative patients. Binary logistic regression with sensitivity analysis was used to test 
the interaction between age and the presence of anti-CarP antibodies.  A p-value of less than 
0,05 was considered statistically significant.
Results
Anti-CarP antibodies are present in JIA patients 
All sera were tested for the presence of anti-CarP antibodies using Ca-FCS and 
Ca-Fib as antigens. In the total JIA cohort 8,1% (19/234) of the patients were positive for 
antibodies reacting to Ca-FCS versus 4,7% (5/107) of controls (p=0,20). In addition 13,2% 
(31/234) of patients versus 2,8% (3/107) of controls were positive for antibodies reacting 
to Ca-Fib (p=0,003). Not all individuals harbored both reactivities and (39/234) 16,7% 
of patients and 8/107 (7,5%) of controls were positive for at least one anti-CarP antibody 
(p=0,028) (data not shown) and 11/234(4,7%) vs 0 of the controls (p=0,017) were positive 
for both anti-CarP reactivities. 
Since the cohort of JIA patients consisted of different disease categories these were analyzed 
separately (Figure 1).  Anti-CarP antibodies were predominantly present in polyarticular 
IgM-RF positive patients (8/19, 421%) as compared to the other JIA categories (p<0.0001). 
This observation was made for both Ca-FCS and Ca-Fib as detecting antigens (Figure 1). 
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Together, these data indicate that the presence of anti-CarP-antibodies in JIA is mainly 
confined to polyarticular IgM-RF positive patient group.
Figure 1 IgG anticarbamylated protein (anti-CarP) antibodies are present in juvenile 
idiopathic arthritis (JIA) sera. A cut-off for positivity (horizontal line) was determined 
using the mean plus two times the SD of the healthy controls. Antibodies against Ca-FCS (A) 
and Ca-Fib (B) in the sera of JIA patients and healthy controls are depicted in aU/mL. (C) 
Results of anti-CarP antibodies: positivity above cut-off per JIA category in absolute number, 
percentage and significance (NS, not significant, *p<0,05, **p<0,01). FCS, fetal calfs serum; RF, 
rheumatoid factor.
Anti-CCP and IgM-RF in JIA and in relation to anti-CarP
Comparing anti-CarP antibodies to anti-CCP antibodies and IgM-RF revealed that 53% 
(8/15) of anti-CCP-positive children and 42.1% (8/19) of IgM-RF-positive children were 













in ACPA and IgM-RF-negative children as 57,9% (11/19) of anti-CarP-positive children 
were negative for anti-CCP antibodies and 27,3% (3/11) were negative for IgM-RF. In total 
9 JIA patients were positive for IgM-RF, anti-CCP and anti-CarP (Ca-FCS and/or Ca-Fib). 
All triple positive patients were part of the ABC register.
Correlation with clinical features
Disease duration at sample collection, ANA status or age (at onset or at sample collection) 
was not associated with the presence of anti-CarP-antibodies. In addition, in the group 
previously described by Albers[20] we did not find an association of anti-CarP positivity 
with disease activity measured by time-in-active-disease at the time of sampling. 
Within the ABC register cohort no association was found between the presence of anti-CarP 
antibodies and ACR-Pedi 30 response[23] or reaching inactive disease at 15 months after 
start of anti-TNF treatment.[24] The cross-sectional nature of this study comprising three 
cohorts did not allow further detailed clinical association studies.
Discussion
Here we report that anti-CarP antibodies, initially identified in samples of adult RA-patients, 
are also present in (categories of) JIA. The detection of anti-CarP antibodies, especially in 
the IgM-RF-positive JIA category, reflects the similarity between RA and polyarticular IgM-
RF positive JIA. The presence of anti-CarP antibodies in anti-CCP-negative RA is associated 
with a more severe disease course as expressed by radiological damage.[15] In our analyses 
information on radiographic damage is currently not available. We did not observe an 
association between anti-CarP antibodies and time-in–active-disease or clinical response 
to anti-TNF therapy but this could be due to lack of power. Disease severity differed across 
the three studies, but in general a severely affected group was collected as represented by 
the high percentages of polyarticular JIA and the use of biologicals. Although the numbers 
are too small to draw conclusions we observed that the triple positive sera (IgM-RF, anti-
CCP and anti-CarP) were all confined to the ABC group that represent severe cases. 
One limitation of this study is the cross-sectional nature of the sera used. Although this 
contributed to a large sample size detailed analyses of the association between the presence 
of anti-CarP antibodies and clinical outcome were not possible, as patients were included 
at different follow-up times and clinical parameters were recorded differently in each study.
In conclusion, anti-CarP antibodies are not only present in RA patients, but are also 
detectable in patients with JIA. They are present predominantly in the polyarticular RF-
positive JIA category in both anti-CCP-positive and negative patients. Studies dedicated to 
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the diagnostic and prognostic value of anti-CarP-antibodies for (categories of) JIA patients 
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Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid 
arthritis (RA) and arthralgia patients at risk to develop RA. To what extent these 
auto-antibodies are specific for RA is unknown. Therefore, we investigated the diagnostic 
performance of the presence of anti-CarP antibodies for RA in a setting of early arthritis. 
Method
Anti-CarP antibodies were detected using carbamylated-fetal calf serum as substrate. Anti-
CCP2 antibodies were measured using ELISA and IgM rheumatoid factor (RF) as part of 
routine care. Sera were derived from patients in the Leiden Early Arthritis Clinic (EAC) 
cohort obtained at inclusion. Test characteristics were determined using the fulfillment of 
the 2010 RA criteria after 1 year as outcome.
Results 
In total 2,086 early arthritis patients were studied regarding the presence of anti-CarP 
antibodies. We observed that the sensitivity and specificity of the presence of anti-
CarP antibodies for RA were respectively 44% and 89%. As a reference sensitivity and 
specificity of the presence of anti-CCP2 antibodies were respectively 54% and 96% and of 
IgM-RF 59% and 91%. Patients harboring anti-CarP antibodies not classified as RA were 
mainly diagnosed with undifferentiated arthritis and less frequently reactive arthritis and 
psoriatic arthritis. 
Conclusion 
Anti-CarP antibodies are predominantly present in RA but can also be detected in other 














Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting synovial 
joints. RA can be classified using the 2010 American College of Rheumatology/European 
League Against Rheumatism classification criteria (2010 ACR/EULAR criteria) for 
rheumatoid arthritis [1]. In this quantitative system points can be obtained from: joint 
involvement, auto-antibodies, acute phase reactants and duration of symptoms [1]. 
Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are included 
in the 2010 ACR/EULAR criteria because of their high sensitivity and specificity in RA 
patients [1]. The presence of either ACPA or RF contributes 2 points and a ‘high’ level 
of either ACPA or RF contributes 1 extra point. The sensitivity of ACPA (~67%) for RA 
is comparable to IgM-RF (~69%) while their specificity (~95%) is higher than that of 
IgM-RF (~85%) [2]. Recently, we identified anti-carbamylated protein (anti-CarP) 
antibodies in both anti-cyclic citrullinated peptide 2 (anti-CCP2) antibody positive and 
negative RA patients [3-5]. Anti-CarP antibodies target proteins which are modified through 
a post-translational modification named carbamylation [6]. Carbamylation is mediated 
by cyanate which mainly modifies lysine residues. The level of cyanate is in equilibrium 
with urea and can be increased for example during renal failure, during smoking and 
during inflammation through a mechanism depending on myeloperoxidase (MPO) [7], 
the level of which is increased in RA patients [8]. The process of carbamylation is not 
restricted to RA but the formation of antibodies against these modified proteins is. Since 
the presence of anti-CCP2 antibodies is strongly associated with the HLA-Shared Epitope 
(SE) alleles and smoking, there is no association between anti-CarP antibodies and smoking 
after the correction for anti-CCP2 antibodies [4]. Anti-CarP antibodies are also not 
associated with  HLA-SE following the correction for anti-CCP2 antibodies but possibly 
with HLA-DR*3 [4]. How anti-CarP antibodies would contribute to arthritis is unknown but 
may involve immune complex formation between anti-CarP antibodies and carbamylated 
proteins in the joint. 
The presence of anti-CarP antibodies in anti-CCP2 antibody negative RA patients was 
associated with increased disease activity [5,9] and with a more severe joint damage [3,9,10]. 
Anti-CarP antibodies were also found in about 40% of RF and/or ACPA positive arthralgia 
patients, who have joint pain without clinically detectable arthritis [11]. Comparable to 
ACPA, also anti-CarP antibodies are independently associated with the risk of developing 
RA in these arthralgia patients [11]. Anti-CarP antibodies can be detected in serum many 
years before the clinical diagnosis of RA [10,12,13] and are independently associated with 
increased joint damage at the baseline of RA diagnosis [10].
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Since anti-CarP antibodies have prognostic value in RA patients we are interested in their 
diagnostic performance for RA in comparison to ACPA and RF in a clinically relevant 
setting of early arthritis.  
Patients and methods
Patients 
We analyzed baseline sera of patients included in the Leiden Early Arthritis Clinic (EAC) 
cohort, which contains patients with arthritis of at least one joint and a symptom duration 
less than 2 years [13].   We measured the presence of anti-CarP, anti-CCP2 antibodies and 
IgM-RF in the sera of 2,086 unselected consecutive EAC sera that were collected between 
1993 and 2011. The outcome was the diagnosis after 1 year of disease, we classified RA by 
strictly applying the 2010 ACR/EULAR criteria. [1].  Disease categories containing less 
than 20 patients were merged as “other” rheumatic diseases. The control sera were collected 
from healthy, non-arthritic, inhabitants of the Leiden area. The protocols were approved by 
the Leiden University Medical Center ethics committee and informed consent was obtained. 
Anti-CarP, anti-CCP2 and IgM-RF measurements
Anti-CarP antibodies were detected using carbamylated Fetal Calf Serum as antigen 
as described before [3,10,12]. IgM-RF was determined as part of routine care and 
anti-CCP2 ELISA (Euro-Diagnostica) was performed following the manufacturer’s 
instructions. The cut-offs for the anti-CarP antibody ELISA was set as the mean plus two 
times the standard deviation (SD) of the healthy controls. 
Statistical analysis 
Statistical analysis was performed with SPSS version 20.0 (SPSS Inc., Chicago, USA). Dunn’s 
multiple comparison test were performed to compare the levels of anti-CarP antibodies 
between diagnoses. Chi-square test with multiple testing correction was performed to 
compare the percentages of anti-CarP antibodies, anti-CCP2 antibodies and IgM-RF 
positive patients in different types of arthritis. The sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative 
likelihood ratio (LR-) of anti-CarP antibodies for RA were calculated. The area under 
the receiver operator characteristic curve (AUC) of anti-CarP antibodies for RA was 














Sensitivity and specificity of anti-CarP antibodies for RA
The Leiden EAC cohort comprises patients with several forms of recent onset arthritis which 
can be encountered in the setting of an outpatient clinic [14]. Of the 2,086 patients analyzed 
969 patients (47%) were classified with RA and 493 (24%) patients as undifferentiated 
arthritis (UA). A complete overview of the diagnoses is presented in Figure 1. We observed 
that anti-CarP antibodies were present in 26% of all patients analyzed and in 2% of 
the healthy controls. The test characteristics were subsequently determined with RA 
according to the 2010-criteria as outcome. The sensitivity of detection of anti-CarP antibodies 
in RA patients was 44% and the specificity of anti-CarP antibodies for RA 89%. In the ACPA 
negative stratum the sensitivity and specificity were respectively 12% and 91%. 
Figure 1. Distribution of anti-CarP antibodies in sera of patients suffering from early 
arhtritis The number of controls and patients in each disease and the levels of anti-CarP 
antibodies in the serum of each individual are shown. Horizontal dashed line indicates cut-off. 
Abbreviations used: RA; Rheumatoid Arthritis, UA; Undifferentiated Arthritis, PsA; Psoriatic 
Arthritis, OA; inflammatory Osteo Arthritis, ReA; Reactive Arthritis (bacterial and viral), SpA; 
Spondylarthropathy with peripheral arthritis, RS3PE; Remitting Seronegative Symmetrical 
Synovitis with Pitting Edema, Sarc; Sarcoidosis, Ps-Gout; Pseudo Gout. 
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Diagnostic performance of anti-CarP antibodies in relation to  
anti-CCP2 and RF for diagnosing RA
The performance of detecting anti-CarP antibodies for diagnosing RA was compared 
to that of anti-CCP2 and RF. We observed a sensitivity for RA of respectively 44%, 54% 
and 59% for anti-CarP, anti-CCP2 and RF, with a specificity of respectively 89%, 96% and 
91% (Table 1). The LR+ of anti-CarP antibodies for RA was 4.2 which was lower than 
the LR+ of anti-CCP2 antibodies (12.9) and IgM-RF (6.9). The LR- for anti-CarP 
antibodies (0.62) was slightly higher compared to anti-CCP2 antibodies (0.48) and IgM-
RF (0.44). Within the total study population, the AUC of anti-CarP positivity was 0.67 
(95%CI 0.64-0.69) (Figure 2A). In anti-CCP2 negative early arthritis patients it was 0.52 
(95%CI 0.48-0.55) suggesting that knowledge on anti-CarP auto-antibody status added only 
limited information for diagnosing RA.
Table 1. The test characteristics of different autoantibodies in RA
Sensitivity Specificity PPV NPV LR+ LR-
anti-CarP 44% 89% 78% 65% 4.2 0.62
anti-CCP2 54% 96% 94% 64% 12.9 0.48
IgM-RF 59% 91% 86% 72% 6.9 0.44
Anti-CarP in anti-CCP–neg pt 12% 91% 37% 71% 1.3 0.97
A comparison is provided on the test characteristics of anti-CarP, anti-CCP and IgM RF for diagnosing 
RA. In addition the performance of anti-CarP in the CCP2 negative stratum is analyzed. Abbreviations 
used: PPV; positive predictive value, NPV; negative predictive value, LR+; positive likelihood ratio,  
LR-; negative likelihood ratio.
Figure 2. Anti-CarP antibodies in relation to ACPA and IgM-RF in RA and other forms of 
early arthritis (A) Receiver Operator Curves and AUC analyses of dichotomous data of anti-
CarP antibodies in the whole cohort. (B) Distribution of positivity for anti-CarP antibodies, 
anti-CCP2 antibodies and IgM-RF in the patients diagnosed with RA. (C) Distribution of 
these autoantibodies in the patients diagnosed with the non-RA forms of early arthritis. 
Both for all individuals for whom data on anti-CarP and CCP2 and RF were available 
(n=934 for RA and n=780 for non-RA). (D) Odds Ratio’s for having the diagnosis RA based on 
the presence of one, two or three autoantibodies relative to having zero autoantibodies. 
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Occurrence of anti-CarP antibodies in other forms of arthritis
In figure 1 the level of anti-CarP antibodies in the sera of individual types of early arthritis 
are depicted. Anti-CarP antibodies were most prevalent in RA, but were also detected in 
other forms of early arthritis (table 2), similar to ACPA and RF. This does not seem to be 
restricted to certain forms of early arthritis, possibly with the exception of pseudogout 
(table 2). Analyzing the anti-CarP positive non-RA early arthritis patients (n=120) separately 
revealed that these patients were mainly diagnosed as undifferentiated arthritis (42%), 
reactive arthritis (9%), psoriatic arthritis (9%) or peripheral spondyloarthritis (8%). 
Comparing the levels of the anti-CarP antibodies in anti-CarP-positive patients across 
the different forms of early arthritis revealed that the levels were significantly higher in RA 
compared to the non-RA conditions (p<0.05 in all conditions). However, also in other forms 
of arthritis high levels were detected occasionally (Figure 1). 
Table 2. Prevalence of different autoantibodies in early arthritis patients with various diagnoses
RA UA ReA Gout Ps-gout PsA OA Sarc SpA RS3PE other
anti-CarP 44% 10% 16% 8% 0% 9% 11% 9% 15% 4% 17%
anti-CCP2 54% 3% 8% 0% 0% 6% 7% 5% 8% 0% 7%
IgM-RF 59% 5% 7% 6% 11% 10% 20% 7% 4% 7% 20%
Abbreviations used: RA; Rheumatoid Arthritis, UA; Undifferentiated Arthritis, PsA; Psoriatic Arthritis, 
OA; inflammatory Osteo Arthritis, ReA; Reactive Arthritis (bacterial and viral), SpA; Spondylarthropathy 
with peripheral arthritis, RS3PE; Remitting Seronegative Symmetrical Synovitis with Pitting Edema, Sarc; 
Sarcoidosis, Ps-Gout; Pseudo Gout. The percentages indicate the proportion of patients positive for one of 
the three autoantibodies analyzed in all samples available for each of the diagnoses.
Even though anti-CCP2 antibodies and IgM-RF are both part of the 2010 classification 
criteria, some patients positive for these autoantibodies had diagnoses other than RA 
(table 2). We did not observe a non-RA condition that harbored significantly more anti-CarP, 
anti-CCP2 antibodies or IgM-RF positive patients compared to any other non-RA conditions 
(p>0.05 in all conditions).  The distribution of anti-CarP, anti-CCP2 antibodies and IgM-RF 
in RA and other patients is shown in figure 2 B and C. In the RA patients the three antibodies 
analyzed frequently occur together or as combinations of two autoantibodies, whereas in 
the non-RA group, there are less patients that display double or triple positivity.
Presence of one, two or three autoantibodies and diagnosis RA
When comparing the presence of one, two or three autoantibodies to the patients with 
zero autoantibodies we observed that with increasing numbers of autoantibodies the OR of 
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having the diagnosis RA highly increased (Figure 2D). For the group with one autoantibody 
the OR is 3.8 (CI 2.9-5.0), for two autoantibodies this is 20.9 (CI 12.7-34.3) and increases 
for three autoantibodies to 112.2 (CI 52.4 – 240.5), with all the groups significantly different 
from the zero autoantibodies reference group (p<0.0001).
The high OR’s observed for the double and triple positives may be expected as 
ACPA and RF are part of the 2010-criteria. However, it is important to note that 
comparing the ACPA and RF double positive patients (OR 36.7 (CI 16.9-79.9)) to 
the ACPA, RF and anti-CarP, triple positive group (112.2 (CI 52.4 – 240.5)), there is an 
additional effect of OR 3.0 (1.1-8.9) p= 0.04.
Discussion
Here we have analyzed the sensitivity and specificity of detecting anti-CarP antibodies 
for RA in a setting of early arthritis encountered at the rheumatology outpatient clinic. 
The sensitivity of the presence of anti-CarP antibodies for RA patients is slightly lower 
than that of anti-CCP2 antibodies and IgM-RF. The specificity of detection of anti-CarP 
antibodies is similar to IgM-RF and is slightly lower than anti-CCP2 antibodies. Even 
though anti-CCP2 antibodies and IgM-RF are both part of the 2010 classification criteria, 
still individuals positive for these autoantibodies are also identified in the non-RA arthritis 
groups, as has also been reported before [15-17] . Therefore, it may not be surprising 
that anti-CarP antibodies, not being part of the 2010 classification criteria, can also be 
present in arthritic conditions other than RA. We have adhered very closely to definition 
when the 2010-classification criteria may be applied and have not considered patients for 
the possible diagnosis RA if their synovitis was more likely explained by another diagnosis 
[1]. Comparing the data on the sensitivity and specificity of detection of anti-CarP antibodies 
for RA using either the 2010-criteria to the 1987-criteria (data not shown) gave almost 
identical results. With the only exception that when using the 1987-criteria the presence of 
anti-CarP antibodies in undifferentiated arthritis (UA) patients was significantly associated 
with future development of RA independent of ACPA and RF, similar to what we observed 
before for arthralgia patients [11]. When the 2010-criteria were used this was not the case 
(data not shown). Patients are frequently double positive for anti-CCP and anti-CarP 
antibodies and since anti-CCP has a more prominent role in the 2010-criteria this may 
explain why anti-CarP antibodies are associated with conversion of UA to RA using 
the 1987-criteria but not when using the 2010-criteria. 
So far we have applied a cut-off for positivity defined as the mean plus two times 
the standard deviation of a set of healthy control sera for anti-CarP antibody ELISA [3,11,13]. 













was 0.67 whereas in the anti-CCP2/RF negative group it was only 0.52. This indicates that 
for purely diagnostic purposes the presence of anti-CarP antibodies is not discriminating 
in the anti-CCP2/RF negative stratum. However, we have previously been able to identify 
a prognostically relevant group of RA patients who were clinically distinct from the 
double negative patients regarding disease activity and especially joint destruction using 
our current cut-off [3], an observation now confirmed in other studies [9,10]. In our view 
the current definition of the cut-off is reasonable and we welcome replication of these 
findings in other cohorts. 
The diagnosis of RA is predominantly based on clinical observations with possible supportive 
information from serology [18]. However, as we are moving forward to identifying persons 
in the pre-RA phase where the full clinical picture of RA is not yet apparent, biomarkers 
will become more important. We have previously shown anti-CarP antibodies can already 
be present years prior to clinical onset of RA [10,12,13] and that that the presence of 
anti-CarP antibodies in addition to RF and ACPA provided relevant information on future 
development of RA [11]. The high OR for RA in triple positive early arthritis patients 
observed in the current study may suggest that triple positivity may also be used to identify 
future RA patients among individuals that do not yet display clinical symptoms. 
In the current study we observed that anti-CarP antibodies occur in almost all forms of early 
arthritis. Although at lower frequencies, also anti-CCP antibodies were detected in many 
other forms of arthritis (Table 2) [15-17]. Whether or not anti-CarP positive patients with 
diagnoses other than RA have a different disease course than the anti-CarP negative patients 
the same diagnosis is a subject of future studies. 
Conclusions
Anti-CarP antibodies are predominantly present in RA but can also be detected in small 
subsets of patients suffering from other forms of early arthritis. 
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In this thesis we report the presence of anti-carbamylated protein (anti-CarP) antibodies 
in a subset of patients suffering from established rheumatoid arthritis (RA) (chapter 2),(1) 
juvenile idiopathic arthritis (JIA) (chapter 5) (2) or one of the conditions preceding RA, such 
as undifferentiated arthritis (UA) (chapter 7), arthralgia (chapter 4) (3) or asymptomatic 
period before the onset of clinical symptoms of RA (chapter 6).(4) The time points when 
anti-CarP antibodies first appear in asymptomatic individuals are comparable to that of anti-
citrullinated protein antibodies (ACPA) but significantly earlier than rheumatoid factor (RF) 
(chapter 6).(4) In arthralgia patients, the presence of anti-CarP antibodies is independently 
associated with the future development of RA (chapter 4).(3) In ACPA-negative RA 
patients, the presence of anti-CarP antibodies is associated with more severe joint damage 
in the disease course (chapter 2).(1) Overall these studies highlight anti-CarP antibodies 
as a novel and interesting autoantibody system with potentially important implications 
in the diagnosis and prognosis of RA. Regarding this series of studies, several issues are 
 worthwhile to be discussed. 
The specificity and reproducibility of the anti-CarP antibody ELISAs
Since the anti-CarP antibody ELISAs were the major technique which we applied in chapter 
2-7,(1-5) its reproducibility is crucial for the validity of our conclusions. Therefore, we 
performed several internal control experiments to judge their reproducibility. The intra-
assay and inter-assay variability of anti-carbamylated fetal calf serum (anti-Ca-FCS) and 
anti-carbamylated fibrinogen (anti-Ca-Fib) ELISAs were both around 10% and 15%. In 
repeated measurements, the chances for negative samples becoming positive and vice versa, 
were generally around 5% in both anti-Ca-FCS and anti-Ca-Fib ELISA’s. The samples of 
which anti-CarP antibody levels are around the cut-off line have relatively high chance to 
change their status. These data suggests a certain degree of variation in anti-CarP ELISAs. 
However, we have also observed that integrating data of repeated measurements of anti-CarP 
antibody ELISAs increased the effect size of all our reported clinical associations (chapter 
2,4).(1,3) This observation suggests that random variation might contribute to a great part 
of all variation of our assays. 
Furthermore, recently we saw independent replications of our two findings (chapter 2, 6). 
These replications include the presence of anti-CarP antibodies in both ACPA positive 
and ACPA negative RA patients (6) and their association with joint damage after correted 
for the presence of ACPA (chapter 2),(7-10) the presence of anti-CarP antibodies before 
the appearance of RA symptoms in asymptomatic individuals (chapter 6). With the help 













independent cohorts. Therefore we are convinced that the possibility that our previous 
published conclusions are chance findings is very low.
When generating the first version of the anti-CarP antibody ELISA we choose to use Ca-
FCS as the antigen because FCS contains a wide mix of proteins and is readily available and 
relatively cheap. Carbamylated human serum is a potentially better source of antigens but 
the interference of human IgG in the ELISA cannot be easily avoided. Later we identified 
carbamylated human fibrinogen as another antigen for anti-CarP antibodies, which is our 
first identified human protein antigen of anti-CarP antibodies. 
Since homocitrulline structurally highly resembles citrulline, it is possible that anti-CarP 
antibodies would be cross-reactive to citrullinated antigens. Here we carefully discussed this 
possibility with respect to our previous results. When analysing the RA patients from the 
Leiden early arthritis cohort, we observed that 9.4% of the patients are anti-CarP antibody 
positive (defined as either anti-Ca-FCS or anti-Ca-Fib antibody positive) and ACPA negative 
(defined as anti-cyclic citrullinated peptide 2 (CCP2) antibody negative), 9.6% are ACPA 
positive and anti-CarP antibody negative, 37.3% are double negative and 43.7% are double 
positive. In this double positive group we observed patients whose anti-CarP antibodies and 
ACPA totally do not cross-react to the other type of antigens and patients whose anti-CarP 
antibodies and ACPA are cross-reactive to the other type of antigens to a certain degree 
(chapter 3).(5) In a small double positive RA cohort, we used a CCP2 peptide bound column 
to deplete anti-CCP2 antibodies in patients’ serum samples. After depletion, the median 
percentage of remaining anti-Ca-FCS antibodies in these samples is 70% (interquartile 
range, IQR: 47%-87%) (chapter 3).(5) The remaining anti-Ca-Fib antibody in serum 
samples is lower (median: 27%, IQR: 18%-58%). This higher cross-reactivity of anti-Ca-Fib 
antibodies might be explained by the hypothesis that some B cell receptors (BCR) and/or 
T cell receptors (TCR) are able to recognize both citrullinated and carbamylated epitopes/
peptides of fibrinogen. 
Anti-CarP antibodies in mice
Even though ACPA are considered to be a highly successful serological marker in RA 
patients, their importance in mouse arthritis models is far less clear. Appearance of ACPA 
without immunization with citrullinated antigens was reported in the collagen induced 
arthritis (CIA) model of DBA1 mice (12-14) but this observation is in debate.(15) A 
recent study suggested that the appearance of ACPA in CIA mice depends on their genetic 
background.(14) Appearance of ACPA following immunization of citrullinated antigens was 
reported in several mouse strains in the presence or the absence of arthritis.(16-18) However, 
whether ACPA can induce or exacerbate symptoms of arthritis on DBA1 and Balb/c mice is 
also in debate.(13,17,18)
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Following our studies on the presence of anti-CarP antibodies in RA patients, our team has 
studied the presence and the role of anti-CarP antibodies in arthritis mouse models. Using 
sera of mice with CIA we observed the presence of anti-CarP antibodies, but not anti-CCP2 
antibodies, in the majority of DBA1 and some of the C57BL/6 mice. The onset of CIA was 
preceded by an increase of anti-CarP antibody levels. This observation is in line with the 
data that in asymptomatic blood bank donors there is a clear rise in the levels of anti-CarP 
antibodies prior to the clinical onset of RA (chapter 6).(4) 
As only part of the C57BL/6 mice developed CIA in this setting this allowed us to analyse 
the relationship between the presence of anti-CarP antibodies and clinical manifestation 
of arthritis. The appearance of anti-CarP antibodies in C57BL/6 mice was not limited to 
the mice which developed arthritis. This observation is in line with the observation that we 
can detect anti-CarP antibodies in the healthy population as well as in individuals prior to 
the onset of clinical symptoms (chapter 4,6).(3,4)
As a control DBA mice were injected with CFA only instead of the combination of CFA 
and CII and some of them also developed anti-CarP antibodies. However, the speed and 
magnitude of anti-CarP antibody responses were clearly associated with the presence of 
arthritis. In addition the presence of anti-CarP antibodies in the mice immunized with CFA 
only was largely limited to mice with significant tail damage and systemic inflammation as 
 a consequence of the immunization procedure.
The immunization of DBA1 mice with carbamylated ovalbumin and CFA also invoked 
a strong anti-CarP antibody response which is cross-reactive to other carbamylated antigens. 
Currently our team is generating mouse monoclonal anti-CarP antibodies to study the role of 
anti-CarP antibodies in arthritis and to identify more antigens of this auto-antibody system. 
In summary, the hypothesis that ACPA/autoantibodies play a key role in the pathogenesis 
of RA still awaits solid and repeatable animal data. The presence of anti-CarP antibodies 
may offer an alternative and potentially more powerful tool to study the generation and 
contribution of autoantibodies in murine models of arthritis. 
Autoantibodies in the pathogenesis of RA
Despite many years of intensive research, the pathogenesis of RA remains to be elusive. 
Generation of ACPA is believed to be a hall mark in the pathogenesis.(19) Genetic 
predisposing and environmental factors, as elaborated in the introduction, are suggested 
to contribute to the break of tolerance and the generation of autoantibodies. However, 
asymptomatic individuals can harbor autoantibodies without developing to RA for many 













of RA. Currently, it is unclear if a second environmental stimulus is compulsory for the onset 
of symptoms, since the autoantibody-antigen system may develop, as the recognition of fine-
specificities, isotype usage and avidity of autoantibodies increase over time. The symptoms 
of joints may appear after sufficient amount of modified proteins have accumulated on 
e.g. matrix molecules. Detailed analysis on the presence of citrullinated and carbamylated 
proteins in the inflamed joints of mice suffering from CIA and in samples from human RA 
patients is currently underway. Preliminary data clearly indicated that in both mice and 
human beings, there are carbamylated proteins in the inflamed joints.(20) After binding 
to ACPA and/or anti-CarP antibodies, the immune complexes can initiate inflammation 
via complement activation and/or attraction of leucocytes and ultimately lead to chronic 
inflammation and bone erosion. Based on this hypothesis, ACPA and anti-CarP antibodies 
may lead to tissue destruction through the same pathways, both in orchestra with RF.  As 
we have shown in chapter 6,(4) either ACPA or anti-CarP antibodies may appear earlier in 
asymptomatic blood bank donors who developed to RA later. The epitope-spreading across 
these two types of auto-antigens may occur no matter which autoantibody system appeared 
first. Whether or not ACPA and anti-CarP antibody responses are initiated in the joints is 
not known but unlikely. The presence of anti-CarP antibodies implies that the citrullination 
is not indispensible in the pathogenesis of autoantibody positive RA. Taking the risk factors, 
such as smoking and chronic inflammation into account, one could speculate that the lungs 
and or other sites of chronic inflammation may actually be the places where the tolerance 
against these post-translationally modified proteins is broken. But the elucidation of these 
processes awaits experimental proof. 
We cannot readily detect autoantibodies in RA patients against glycated, carbonylated 
and tobacco smoke treated FCS (unpublished data). Interestingly, anti carbamylated low 
density protein (anti-Ca-LDL) antibodies were found cross-reactive to malondialdehyde 
(MDA)/malondialdehyde acetaldehyde (MAA) modified and carbonylated LDL in healthy 
individuals.(21,22) MDA and MAA modified proteins belong to advanced oxidation protein 
products which occur during lipid peroxidation.(18) MDA and MAA modifications occur 
on lysine, the same as carbamylation.(18) Previously we have also detected the presence 
of anti-Ca-LDL antibodies (unpublished data) in RA patients. It would be interesting to 
study if anti MDA/MAA modified/carbonylated LDL antibodies may appear in RA patients 
independent of anti-Ca-LDL antibodies.
The future of anti-CarP antibodies
The characteristics of anti-CarP antibodies, in comparison with ACPA and IgM-RF, are 
listed in table 1. In summary, the specificity and sensitivity of anti-Ca-FCS and anti-Ca-Fib 
antibodies in RA patients are slightly lower than ACPA and RF-IgM (chapter 7). Similar to 
ACPA, anti-CarP antibodies have prognostic value in RA patients and predictive value in pre-
120
RA stage patients (chapter 2,4).(1,3) Recently together with a Japanese group we confirmed 
the presence of anti-CarP antibodies in the Japanese population (not published), suggesting 
the presence of anti-CarP antibodies is not limited to the Caucasian population. Currently 
we are collaborating with INOVA diagnostics to develop the second generation anti-CarP 
ELISA which may have better sensitivity, specificity and reproducibility compared to 
the assays we are currently using. If the new generation assay can considerably improve these 
aspects of anti-CarP ELISA, the anti-CarP antibodies might have the value to be included in 
the next version of RA classification criteria. 
Table 1 Comparison of ACPA, anti-CarP antibodies, RF in our studies
IgM-RF ACPA1 Anti-CarP antibodies2
Sensitivity in RA3,4 59% 54% 44%
Specificity in RA3,4 91% 96% 89%
Isotype switch3,5 yes yes yes
Sensitivity in UA3,6 28% 25% 30%
Presence in Arthralgia7 yes yes yes
Presence before the onset8 yes yes yes
Presence in JIA9 yes yes yes 
Predict joint damage3,5 no yes yes
Predict arthralgia to RA4,7 no yes yes
Predict UA to RA3,6 yes yes no
Predict DMARD free remission3,5,10 no yes no
1defined as anti-CCP2 antibodies 
2defined as positive for either anti-Ca-FCS or anti-Ca-Fib antibodies 
3in LUMC early arthritis cohort 
4established RA patients according to 1987 ACR RA criteria 
5studied in RA population 
6defined as UA patients according to 1987 ACR RA criteria in early diagnosis 
7in arthralgia cohort from Reade institute 
8in asymptomatic blood donor cohort from Reade institute 
9in a combination of JIA cohorts as described in the paper “Anti-carbamylated protein (anti-CarP) 
antibodies are present in sera of Juvenile Idiopathic Arthritis (JIA) patients” 
10not published
It is known that ACPA positive RA patients respond better to B cell depletion therapy and 
their level is associated with treatment effect.(19) ACPA positive UA patients, but not ACPA 
negative patients, respond to disease modifying antirheumatic drugs (DMARDs).(25) Yet, 
the relationship between the anti-CarP antibody status and the responses to treatments 













supposed to be the same as ACPA, they may be associated with the treatment effects of B cell 
depletion therapy in RA patients and DMARDs in UA patients as well.
ACPA positive RA patients have rather different genetic risk loci compared to ACPA negative 
RA patients.(26) They are also suspected having different pathogenesis. Although anti-CarP 
positive and ACPA positive RA patients may have different HLA class II susceptibility, we 
assume anti-CarP antibodies positive/ACPA negative RA patients should share similar non-
HLA genetic risk loci as ACPA positive patients. After excluding anti-CarP antibody positive 
patients from ACPA negative patients, it may be easier to find out the true genetic risk factors 
of autoantibody negative RA patients and unravel their pathogenesis. 
Conclusions
In conclusion, we discovered the presence of a new autoantibody system in RA and pre-
RA stage patients. This new autoantibody system, anti-CarP antibodies, may contribute to 
the prediction and prognosis of RA. The discovery of anti-CarP antibody also expanded 
the profile of autoantibody systems in RA, changing the concept that ACPA are unique in 
RA. The presence of anti-CarP antibodies in CIA mice might also offer a new study tool to 
investigate the role of autoantibody in the pathogenesis of RA.
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Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that causes chronic 
inflammation, pain and bone loss in synovial joints. RA patients are a heterogeneous group 
of patients with pronounced differences in disease activity and outcome. This heterogeneous 
group can be subdivided by the presence of autoantibodies. Autoantibody positive and 
negative RA patients were found to have different genetic background, disease development 
processes and responses to treatments. Anti-citrullinated protein antibodies (ACPA) and 
rheumatoid factors (RF) are the two major autoantibodies of RA, which were included 
in the 2010 American College of Rheumatology/European League Against Rheumatism 
classification criteria for RA. RF mainly recognizes the Fc part of IgG and ACPA bind to 
proteins that have undergone the post-translational modification, citrullination, mediated 
by peptidylarginine deiminases. Both ACPA and RF are diagnostic markers for RA patients 
and predictive markers for future development of RA in pre-RA stage patients. ACPA are 
also a prognostic marker for increased bone erosions in RA patients. As ACPA are only 
present in about 67% of the RA patients and some ACPA negative RA patients also have 
severe joint damage, there is a need for additional biomarkers to identify ACPA negative 
patients in need of a more aggressive intervention.  In an attempt to identify additional 
biomarkers to be used for such identification we addressed the presence of antibodies against 
proteins modified by another form of post-translational modification, carbamylation. 
Carbamylation is a post-translational modification in which cyanate reacts to lysines and 
modifies them to homocitrullines. The structure of homocitrulline resembles citrulline 
and is only one methylene group longer than citrulline. It has been shown recently that 
carbamylated proteins may trigger T cell response and autoantibody formation in rodents. 
We hypothesized that anti-carbamylated protein (anti-CarP) antibodies may also be present 
in RA patients as described in this thesis.   
To detect anti-CarP antibodies we developed ELISAs using carbamylated FCS (Ca-FCS) 
and carbamylated human Fibrinogen (Ca-Fib) (Chapter 2). In the Leiden early arthritis 
cohort (EAC) we observed that 45% of the RA patients are positive for anti-Ca-FCS 
IgG antibodies and 43% of the RA patients are positive for anti-Ca-FCS IgA antibodies. 
Similar to the observation for anti-Ca-FCS antibodies, we observed also the presence of 
anti-Ca-Fib antibodies in RA patients, confirming that these antibodies are auto-reactive. 
Next, we wished to analyze whether anti-CarP antibodies are cross-reactive to citrullinated 
proteins and vice versa. To answer this question we performed ELISAs with specially 
designed peptides, inhibition assays and western blots. All these experiments suggested 
that anti-CarP antibodies and ACPA are only partially cross-reactive to the other type of 
post-translationally modified antigens. Besides, 16% of ACPA-negative RA patients are 
anti-Ca-FCS IgG positive and 30% of patients are anti-Ca-FCS IgA positive in the ACPA 













the antigen-binding-part of the antibodies, we generated F(ab’)2. As expected, F(ab’)2 
but not Fc part displayed anti-CarP reactivity and displayed a similarly restricted 
cross-reactivity to citrullinated proteins as intact antibodies. The presence of ACPA in RA 
patients is associated with a more severe clinical disease course as measured by radiological 
damage. We therefore analyzed whether the presence of anti-Ca-FCS antibodies is 
also predictive for a more severe disease course. We observed that patients positive for 
anti-Ca-FCS IgG had more joint destruction over time, also after correction of ACPA and 
RF. In the stratified analyses, the presence of anti-Ca-FCS IgG is associated with a more 
severe joint damage in the anti-cyclic citrullinated pepetide 2 (CCP2) antibody negative 
subgroup but not in the anti-CCP2 antibody positive. 
In Chapter 2 we have studied the cross-reactivity of anti-CarP antibodies to citrullinated 
proteins, in Chapter 3 we quantified this cross-reactivity. The Anti-Modified Citrulline 
(AMC) antibody developed by Dr. Senshu is able to recognize citrullinated epitopes 
irrespective of the neighboring amino acids. Thus we also aimed to verify whether the 
AMC assay could distinguish between citrullinated and carbamylated epitopes. We found 
the “AMC-Senshu” method cannot differentiate citrullinated and carbamylated epitopes. 
This finding does not argue against the notion that citrullinated proteins are present in 
synovial fluid and tissues, since a number of studies confirmed the presence of citrullinated 
proteins by mass-spectrometry fingerprinting. However, our study suggests that the extent 
and nature of citrullination and carbamylation in the joint should be re-evaluated.
In addition we performed ACPA depletion in which more than 98% of ACPA in the 
sera were depleted. The median percentage of remaining anti-Ca-FCS antibodies in the 
sera is 70% (interquartile range, IQR: 47%-87%) and for anti-Ca-Fib antibodies is 27% 
(IQR: 18%-58%). Again these data indicate that next to a potentially cross-reactive 
component also antibodies uniquely specific for carbamylated antigens are present in 
sera of RA patients.
In pre-RA stages such as arthralgia and undifferentiated arthritis (UA), ACPA and RF are 
predictive factors for future progression towards RA. However, at present it is unknown 
whether anti-CarP antibodies exist in arthralgia patients (Chapter 4). We studied whether 
anti-CarP antibodies are present in arthralgia patients and whether their presence associates 
with the development of RA. For this purpose we have used an arthralgia cohort from 
our collaborators in Amsterdam which includes patients who were positive for either 
anti-CCP2 antibodies and/or RF. In this cohort, we could measure baseline sera obtained during 
the arthralgia phase and relate it to clinical onset of RA years later. We observed that 
anti-Ca-FCS antibodies were present in sera of 39% of these arthralgia patients. 
The presence of anti-Ca-FCS antibodies was associated with the development of RA 
in the whole arthralgia cohort after correction for RF and anti-CCP2 antibody status 
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(HR: 1.56; 95%CI: 1.06-2.29; p = 0.023), as well as in the anti-CCP2 antibody positive 
subgroup (OR: 2.231; 95%CI: 1.31-3.79; p = 0.003) but not in the anti-CCP2 antibody 
negative subgroup (p=0.891). After correction for anti-CCP2 antibody level, anti-CarP 
antibody positivity still increased the risk for developing RA in anti-CCP2 antibody 
positive arthralgia patients. Anti-CarP antibody positive patients not only developed RA 
more often but also within a shorter time frame. This association remained significant 
after correction for anti-CCP2 antibody and IgM-RF status or the levels of anti-CCP2 
antibodies and IgM-RF status.
In Juvenile Idiopathic Arthritis (JIA) patients there is a lack of markers that predict severe 
disease. Although ACPA have contributed to the understanding of RA, they are not equally 
useful in JIA patients as their presence in JIA patients is low and merely confined to 
the polyarticular IgM-RF positive category resembling RA. Since most JIA patients are 
ACPA-negativewe investigated whether anti-CarP antibodies are present in sera of JIA 
patients and how they are related to ACPA and IgM-RF (chapter 5). We observed that 8,1% 
of the JIA patients were positive for anti-Ca-FCS antibodies and 13.2% of the patients were 
positive for anti-Ca-Fib antibodies. Both anti-Ca-FCS and anti-Ca-Fib antibodies were 
predominantly present in polyarticular IgM-RF positive patients. Anti-CarP antibodies 
(defined as anti-Ca-FCS or anti-Ca-Fib antibodies) were also found in ACPA and 
IgM-RF-negative patients as 57,9% of anti-CarP positive patients were negative for ACPA 
and 27.3% were negative for IgM-RF. The cross-sectional nature of the cohorts we used 
in this study did not allow an in depth analysis of the association between the anti-CarP 
antibody status and the clinical outcome of JIA patients. 
Early and aggressive intervention in individuals that are developing to RA can prevent 
irreversible bone loss and induce early remission. The presence of autoantibodies could be 
a useful marker to identify the individuals that could benefit most from such intervention. 
Both ACPA and RF can be detected in serum many years prior to the onset of symptoms 
and are thought to be implicated in the disease progression of RA.  The studies presented 
in chapter 6 we analyzed whether anti-CarP antibodies are already present in healthy 
individuals before the diagnosis of RA and how the appearance of anti-CarP antibodies 
relates to the appearance of ACPA and IgM-RF. From the sera of RA patients collected 
prior to the diagnosis we detected the presence of anti-Ca-FCS (26.6%) and anti-Ca-Fib 
antibodies (38.0%). The moment when IgM-RF, anti-Ca–FCS, anti-Ca-Fib and anti-CCP2 
antibodies were detectable for the first time were respectively 10, 14, 14 and 14 years before 
diagnosis of these patients. These are the time points when the first samples of these patients 
were collected. The median (IQR) of time points when anti-CCP2, anti-Ca-FCS, anti-Ca-Fib 
antibodies and IgM-RF first appeared were 6 (3-10), 5 (3-7), 7 (4-10) and 2 (1-5) years before 
the diagnosis. The levels of autoantibodies increased within the majority of followed blood 













increased in 83% (33/40), 78% (31/40), 53% (21/40) and 85% (34/40) of donors. The median 
levels of all autoantibodies start to increase around 5 to 7 years before the diagnosis or RA.
In the studies presented in chapter 7 we compared the sensitivity and specificity of 
anti-CarP antibodies in RA patients with ACPA and RF. We have performed these analyses 
using 2086 samples from the Leiden EAC, comprising all forms of early arthritis as 
encountered in the outpatient clinic. The sensitivity and specificity of anti-CarP antibodies 
for RA are 44% and 89%. As a reference we observed a sensitivity and specificity of 
anti-CCP for RA of 54% and 96% and for RF 59% and 91%. Although anti-CarP antibodies 
are predominantly present in RA patients we observed some anti-CarP antibody positive 
individuals in nearly all other forms of early arthritis. To what extent the presence of 
anti-CarP antibodies in these conditions is associated with clinical presentation or outcome 
will be the focus of future research.
In this thesis we report the presence of anti-CarP antibodies in subsets of patients suffering 
from established RA (chapter 2), JIA (chapter 5) or one of the conditions preceding RA, 
such as UA (chapter 7), arthralgia (chapter 4) or asymptomatic period before the onset of 
clinical symptoms of RA (chapter 6). The time points when anti-CarP antibodies first appear 
in asymptomatic individuals are comparable to that of ACPA but significantly earlier than 
RF (chapter 6). In arthralgia patients, the presence of anti-CarP antibodies is independently 
associated with the future development of RA (chapter 4). In ACPA-negative RA patients, 
the presence of anti-CarP antibodies is associated with more severe joint damage in 
the disease course (chapter 2). Overall these studies highlight anti-CarP antibodies as 
a novel and interesting autoantibody system with potentially important implications in the 





Reumatoïde artritis (RA) is een chronische, systemische, auto-immuunziekte die leidt 
tot chronische ontsteking, pijn en botverlies in synoviale gewrichten. De populatie van 
RA patiënten is heterogeen met nadrukkelijke verschillen in ziekteactiviteit en uitkomst. 
Deze heterogene groep kan worden onderverdeeld op basis van de aanwezigheid 
van autoantilichamen. Autoantilichaam positieve patiënten bezitten ten opzichte van 
autoantilichaam negatieve patiënten andere genetische risicofactoren, ondergaan een ander 
ziektebeloop en reageren anders op medicatie. Anti-gecitrullineerde eiwit antilichamen 
(ACPA) en reuma factor (RF) zijn de twee meest bekende autoantilichamen bij RA. Deze twee 
antilichamen zijn opgenomen in de 2010 American College of Rheumatology / European 
League Against Rheumatism classificatiecriteria voor RA. ACPA binden aan eiwitten die de 
post-translationele modificatie citrullinatie hebben ondergaan onder invloed van peptidyl 
arginine deiminases. RF herkent vooral het Fc gedeelte van IgG. Zowel ACPA als RF zijn 
diagnostische markers voor RA en de aanwezigheid van deze markers is van voorspellende 
waarde voor het ontwikkelen van RA vanuit de RA voorloper stadia. De aanwezigheid 
van ACPA is ook van prognostische waarde voor botafbraak in RA. Omdat ACPA slechts 
aanwezig zijn in ongeveer 60% van de RA patiënten en ook sommige ACPA negatieve 
patiënten toch ernstige boterosies ontwikkelen is er vraag naar additionele biomarkers 
om ACPA negatieve patiënten te identificeren voor wie een agressievere behandeling 
wenselijk zou zijn.
In een poging biomarkers te ontdekken die een dergelijke identificatie mogelijk zouden 
maken zijn wij op zoek gegaan naar antilichamen gericht tegen eiwitten die een andere 
post-translationele modificatie hebben ondergaan, carbamylatie. Carbamylatie is een 
post-translationele modificatie waarbij cyanaat reageert aan lysines en deze lysines 
modificeert tot homocitrullines. De structuur van homocitrulline lijkt veel op die van 
citrulline en is slechts één methyleen groep langer dan citrulline. Het is recent aangetoond 
in proefdiermodellen dat gecarbamyleerde eiwitten autoantilichamen kunnen induceren. 
Hierop vormden we de hypothese dat er bij reumapatiënten antilichamen aanwezig 
kunnen zijn die gecarbamyleerde eiwitten herkennen, anti-gecarbamyleerde eiwit 
antilichamen (anti-CarP).
Om anti-CarP antilichamen te kunnen detecteren hebben we een ELISA opgezet gebaseerd 
op gecarbamyleerd Foetaal Kalf Serum (Ca-FCS) en gecarbamyleerd humaan Fibrinogeen 
(Ca-Fib) (Hoofdstuk 2). In het Leiden Early Arthritis Clinic (EAC) cohort hebben 
we vastgesteld dat 45% van de RA patiënten positief is voor IgG anti-Ca-FCS antilichamen 
en 43% voor IgA anti-Ca-FCS antilichamen. Naast deze anti-Ca-FCS antilichamen konden 
we ook antilichamen meten die aan humaan Ca-Fib bonden, waarmee we auto-reactiviteit 













vertonen naar gecitrullineerde eiwitten en of ACPA kruisreactiviteit vertonen naar 
gecarbamyleerde eiwitten. Om deze vraag te beantwoorden hebben we verschillende 
experimenten gedaan: ELISA’s met verschillende peptides, inhibitie assays en western blots. 
Telkens tonen deze experimenten aan dat er slechts een beperkte mate van kruisreactiviteit 
is. Tevens zien we in de RA populatie dat 16% van de ACPA negatieve patiënten positief 
is voor anti-CarP IgG en 30% voor anti-CarP IgA. Om er zeker van te zijn dat de reactiviteit 
voor gecarbamyleerde eiwitten daadwerkelijk door het antigeen herkennende gedeelte van 
de anti-CarP antilichamen gemedieerd wordt hebben we F(ab)2 gegenereerd. Deze F(ab)2, 
maar niet de Fc gedeeltes, vertoonden anti-CarP reactiviteit en hadden dezelfde beperkte 
mate van kruisreactiviteit als de intacte anti-CarP antilichamen. 
De aanwezigheid van ACPA is geassocieerd met een ernstig ziektebeloop met meer 
radiologische schade. We hebben daarom geanalyseerd of de aanwezigheid van anti-CarP 
antilichamen ook  geassocieerd is met een ernstig ziektebeloop. We hebben vastgesteld 
dat patiënten positief voor anti-Ca-FCS antilichamen meer gewrichtsschade hadden in de 
tijd, zelfs na correctie voor ACPA en RF. In de gestratificeerde analyse is de aanwezigheid 
van anti-CarP IgG geassocieerd met ernstige gewrichtsschade in de anti-Cyclisch 
Gecitrulineerd Peptide 2 (CCP2) antilichaam negatieve subgroep maar niet 
in de anti-CCP2 positieve subgroep.
Hoofdstuk 2 beschrijft het onderzoek naar de kruisreactiviteit van anti-CarP 
antilichamen voor gecitrullineerde eiwitten en in Hoofdstuk 3 wordt de kwantificatie 
van deze kruisreactiviteit gepresenteerd. De anti-gemodificeerde citrulline (AMC) test 
die ontwikkeld is door Dr. Senshu kan citrullines aantonen zonder dat dit beïnvloed wordt door 
de omringende aminozuren. Vanwege de grote structurele overeenkomst tussen citrulline 
en homocitrulline wilden we analyseren of deze methode een onderscheid tussen 
deze twee modificaties zou kunnen maken. We vonden duidelijke aanwijzingen dat 
de AMC-Senshu methode geen onderscheid maakt tussen deze modificaties. Deze observatie 
hoeft niet te betekenen dat de eerdere bevindingen gemaakt met deze methode, bijvoorbeeld 
de aanwezigheid van gecitrullineerde eiwitten in het ontstoken gewricht, niet correct zijn. 
Studies met massa-spectometrie hebben de aanwezigheid van gecitrullineerde eiwitten 
bevestigd. Maar onze studie geeft wel aan dat de huidige gedachten over de aanwezigheid 
en bijdrage van citrullinatie versus carbamylatie in het gewricht wellicht heroverwogen 
moet worden.
Verder hebben we studies gedaan waarbij we ACPA hebben gedepleteerd uit 
ACPA/anti-CarP dubbel positieve sera. De depletie van ACPA-reactiviteit was meer dan 
98%. In deze samples was de mediaan van het percentage anti-Ca-FCS dat nog aanwezig was 
70% (IQR 47%-87%) en van anti-Ca-Fib 27% (IQR 18%-58%). Ook deze data geven weer 
aan dat er in het serum van RA patiënten naast een potentieel kruisreagerende populatie 
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antilichamen ook antilichamen aanwezig zijn die uniek reageren met ofwel gecitrullineerde 
eiwitten ofwel gecarbamyleerde eiwitten.
In pre-RA stadia zoals artralgie en ongedifferentieerde artritis (UA) zijn ACPA en 
RF beschreven als voorspellende factoren voor het toekomstig ontwikkelen van RA. 
In hoofdstuk 4 worden studies beschreven waarin geanalyseerd is of er bij artralgie patiënten 
ook anti-CarP antilichamen voorkomen en of de aanwezigheid van deze antilichamen ook 
geassocieerd is met het toekomstig ontwikkelen van RA. We hebben gebruik gemaakt van 
een artralgie cohort uit Amsterdam waarin patiënten zijn geïncludeerd op basis van het 
hebben van artralgie en positiviteit voor ofwel anti-CCP antilichamen of IgM-RF. In dit 
cohort konden we anti-CarP antilichamen aantonen in 39% van de artralgie patiënten. De 
aanwezigheid van anti-CarP antilichamen was geassocieerd met het ontwikkelen van RA, 
ook na correctie voor anti-CCP antilichamen en RF status. Deze associatie zagen we niet 
als we de anti-CCP2 negatieve groep apart analyseerden. Ook na correctie voor de levels 
van anti-CCP antilichamen was de aanwezigheid van anti-CarP antilichamen nog steeds 
geassocieerd met het ontwikkelen van RA in de anti-CCP positieve populatie. Anti-CarP 
antilichaam positieve patiënten ontwikkelden RA niet alleen vaker, maar ook eerder. Deze 
associatie bleef significant ook na correctie voor anti-CCP2 en IgM-RF status of de levels van 
anti-CCP2 antilichamen en IgM-RF status.
Bij Juveniele Idiopathische Artritis (JIA) is er een gebrek aan markers die een ernstig ziekte 
verloop kunnen voorspellen. Ondanks het feit dat ACPA een rol spelen bij de diagnose en 
prognose van RA, hebben deze autoantilichamen geen prominente rol bij JIA. Vooral omdat 
ACPA vrijwel uitsluitend voorkomen bij de poly-articulaire IgM-RF positieve subgroep 
van JIA die veel lijkt op RA. Omdat verreweg de meeste JIA patiënten negatief zijn voor 
ACPA hebben we in het kader van studies beschreven in Hoofdstuk 5 onderzocht of anti-
CarP antilichamen aanwezig zijn bij JIA en wat de relatie is met ACPA en IgM-RF. Uit deze 
analyses bleek dat 8.1% van de JIA patiënten positief was voor anti-Ca-FCS antilichamen 
en 13.2% voor anti-Ca-Fib antilichamen. Zowel anti-Ca-FCS en anti-Ca-Fib antilichamen 
zijn voornamelijk aanwezig in de poly-articulaire IgM-RF positieve subgroep van JIA. 
Anti-CarP antilichamen (anti-Ca-FCS en anti-Ca-Fib samen) waren ook aanwezig in 
patiënten die negatief waren voor ACPA en of IgM-RF. In totaal waren 57.9% van de anti-
CarP positieve patiënten negatief voor ACPA en 27.3% negatief voor IgM-RF. Vanwege het 
cross-sectionele karakter van de patiënten populatie konden we geen gedetailleerde studies 
doen naar de associatie tussen de aanwezigheid van anti-CarP antilichamen en klinisch 
beloop van de JIA patiënten.
Vroege en agressieve interventie kan in individuen die RA ontwikkelen het irreversibele 
botverlies voorkomen en vroege remissie induceren. De aanwezigheid van autoantilichamen 













zijn bij een dergelijke interventie. Zowel ACPA als IgM-RF kunnen in het serum al 
worden aangetoond jaren voordat de symptomen merkbaar zijn en deze autoantilichamen 
worden geïmpliceerd bij te dragen aan het ziekte proces van RA. In studies beschreven in 
hoofdstuk 6 hebben we geanalyseerd of anti-CarP antilichamen al aanwezig zijn in gezonde 
individuen voordat de diagnose RA is gesteld en ook hoe de aanwezigheid van anti-CarP 
antilichamen zich verhoudt tot de aanwezigheid van ACPA en IgM-RF. In sera van gezonde 
bloedbank donoren, verzameld net voordat bij hen de diagnose RA werd gesteld, konden we 
anti-CarP antilichamen aantonen in 26,6% van de personen voor anti-Ca-FCS en in 38,0% voor 
anti-Ca-Fib. Het moment waarop IgM-RF, anti-Ca-FCS, anti-Ca-Fib en anti-CCP2 
antilichamen voor het eerst konden worden aangetoond waren respectievelijk 10, 14, 14 
en 14 jaar voor de diagnose. Voor veel patiënten was dit het eerste beschikbare monster. De 
mediaan (IQR) van de tijdstippen (in jaren voor diagnose) waarin de antilichamen voor het 
eerst te detecteren waren was 6 (3-10) voor anti-CCP2, 5 (3-7) voor anti-Ca-FCS, 7 (4-10) 
voor anti-Ca-Fib en 2 (1-5) voor IgM-RF. De levels van de autoantilichamen namen toe 
over de tijd in de meeste donoren. We zagen een toename voor anti-CCP2 in 83% (33/40), 
anti-Ca-FCS 78% (31/40), anti-Ca-Fib 53% (21/40) en voor IgM-RF in 85% (34/40) van de 
donoren. De mediane levels nemen voor alle autoantilichamen vooral toe in de periode van 
5 tot 7 jaar voor de diagnose.
In de studies beschreven in hoofdstuk 7 vergelijken we de sensitiviteit en de specificiteit 
van anti-CarP antilichamen voor RA met die van anti-CCP2 en RF. We hebben hiervoor 
analyses uitgevoerd op 2086 sera van patiënten uit het Leiden Early Arthritis Clinic (EAC) 
cohort, bestaande uit patiënten met alle vormen van vroege artritis zoals die in de polikliniek 
voorkomen. De sensitiviteit en specificiteit van de aanwezigheid van anti-CarP antilichamen 
voor RA is 44% en 89%. Ter vergelijking, voor anti-CCP2 is dit 54% en 96% en voor 
IgM-RF 59% en 91%. De anti-CarP antilichamen zijn vooral aanwezig bij RA patiënten, 
maar kunnen ook gevonden worden in enkele patiënten met andere van vroege artritis. 
In welke mate de aanwezigheid van anti-CarP antilichamen in deze niet-RA artritides is 
geassocieerd met klinische presentatie of beloop is het onderwerp van toekomstige studies.
In dit proefschrift beschrijven we de aanwezigheid van anti-CarP antilichamen in een gedeelte 
van de patiënten met RA (hoofdstuk 2), JIA (hoofdstuk 5), of één van de condities die vooraf 
gaan aan RA, zoals UA (hoofdstuk 7), artralgie (hoofdstuk 4) of de asymptomatische fase 
voordat de eerste symptomen zichtbaar worden (hoofdstuk 6). Het tijdstip waarop de anti-
CarP antilichamen voor het eerst detecteerbaar zijn is vergelijkbaar metde eerste detectie 
van anti-CCP2 maar significant eerder dan IgM-RF (hoofdstuk 6). In artralgie patiënten is 
de aanwezigheid van anti-CarP antilichamen, onafhankelijk van ACPA, geassocieerd met 
het ontwikkelen van RA in de toekomst. In ACPA negatieve RA patiënten is de aanwezigheid 
van anti-CarP antilichamen geassocieerd met meer gewrichtsschade tijdens het 
ziekte verloop (hoofdstuk 2). 
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Deze studies geven gezamelijk aan dat anti-CarP een nieuw en interessant autoantilichaam 
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